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Résumé 
Une résistance aux agents anticancéreux utilisés dans le traitement du cancer du sein est 
souvent associée à un échec de traitement.  Des variations dans le devenir des agents anticancéreux 
dans l’organisme, sont des facteurs pouvant expliquer des phénomènes de résistance.  Notre but était 
d’évaluer l’impact des isoenzymes du CYP450s, dans le métabolisme local des agents anticancéreux. 
 Notre premier objectif était de valider un gène rapporteur pour nos analyses de PCR en temps 
réel.  Pour ce faire, nous avons criblé l’expression de 6 gènes rapporteurs dans 23 lignées cellulaires.  
NUP-214 a été démontré comme étant le gène rapporteur le plus stable avec un écart-type de 
seulement 0.55 Ct.  
 Notre deuxième objectif était de déterminer le niveau d’expression des ARNm de 19 isoformes 
du CYP450 dans plusieurs lignées cellulaires du cancer du sein.  Les ARNm des CYP450s ont démontré 
une très grande variabilité entre les lignées cellulaires.  Les isoformes CYP1B1 et CYP2J2 démontrent 
l’expression la plus importante pour la majorité des lignées. 
 Notre troisième objectif était d’évaluer la corrélation entre l’expression des isoformes des 
CYP450s et leur activité métabolique en utilisant les substrats spécifiques du CYP1B1 et 2J2, 7-
éthoxyrésorufine et ébastine, respectivement.  Une forte corrélation (r2=0.99) fut observée entre 
l’activité métabolique vis-à-vis l’ébastine et l’expression du CYP2J2.  De même, le métabolisme du 7-
éthoxyrésorufine était fortement  corrélé (r2=0.98) avec l’expression du CYP1B1.  
En résumé, ces résultats suggèrent que le métabolisme local des agents anticancéreux pourrait 
significativement moduler le devenir des agents anticancéreux dans l’organisme, et pourrait être ainsi, 
une source de résistance. 
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Abstract 
Several types of cancer cells have shown an innate or accute resistance to anti-cancer agents 
which in turn causes a failure in treatment.  This resistance has been suggested to be caused by the 
expression of membrane transporters in cancer cells, as well as inter-individual variability in 
metabolism.  Our interest was to evaluate the implication of CYP450 enzymes in the local metabolism of 
cancer cells. 
 Our first objective was to screen the expression level of six housekeeping genes (HKG) using 23 
different cell lines to determine which gene was the most stable.  We found that NUP-214 was the most 
stable HKG across the panel of cell lines tested, with a standard deviation of only 0.55 Ct. 
 Our second objective was to determine the expression level of 19 CYP450 mRNA isoforms in 
various breast cancer cell lines by RT-PCR.  The CYP450 mRNAs showed a large variability between the 
different cell lines analyzed, where CYP1B1 and 2J2 were strongly expressed in most cell lines.   
 Our third objective was to determine if measurable metabolic activity was present and 
correlates with mRNA expression in these same breast cancer cell lines using the specific substrates 
7-ethoxyresorufin and ebastine for CYP1B1 and 2J2 activities, respectively.  The metabolism of 
7-ethoxyresorufin showed an excellent correlation of 0.98 with CYP1B1 expression while ebastine 
demonstrates a strong correlation (r2=0.99) with 2J2 expression.   
Overall, these results suggest that local metabolism of anti-cancer agents could significantly 
affect drug disposition and be a source of chemoresistance. 
 
Keywords : Cytochrome P450, breast cancer, chemotherapy resistance, drug metabolism, intersubject 
variability 
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INTRODUCTION 
Breast cancer is an important form of cancer that affects both men and women.  In women, 
breast cancer accounts for 28% of all diagnosed cancers, and for 15% of the deaths due to cancer.  In 
2011, an estimated 6,200 women in Quebec (23,400 women and 190 men, in Canada) will be diagnosed 
with breast cancer, and 1,300 women in Quebec (5,100 women and 55 men, in Canada) will die due to 
breast cancer.  Currently, it is estimated that the probability of developing breast cancer is 1 in 9, and 
the chance of death due to breast cancer is 1 in 29 (according to the Canadian Cancer Statistics 2011).  
Therefore, breast cancer is a disease which affects so many people, and merits the time and funding 
required to find a cure. 
Great advancements have been made in the diagnosis and treatment of breast cancer.  Large 
improvements have been made to mammography which can now detect smaller tumours while using 
less X-rays.  Additionally, regular mammography screenings have been implemented leading to earlier 
detection, ultimately leading to better prognoses.  Targeted treatments for breast cancers have also 
been developed leading to greater survival.  While great advancements have been made in therapeutics, 
inter-subject variability and anti-cancer resistance remains to be a key issue in breast cancer patients.   
Therefore, this work has been focused on finding a cause of anti-cancer resistance and 
inter-subject variability in the response to anticancer agents.  Our focus was on the local expression of 
Cytochrome P450s, key enzymes in the metabolism of xenobiotics, in breast cancer. 
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1. BREAST CANCER PATHOLOGY 
The use of molecular classifications is not only important for breast cancer patients, but also for 
researchers.  Studies have shown that gene expression varies between subtypes, and therefore gene 
expression differences observed in vitro need to be related back to the molecular subtype, especially 
when large inter-subject variability is observed. 
1.1. CANCER CELL LINES CHARACTERISTICS/MOLECULAR CLASSIFICATIONS 
Treatment options for breast cancer tumors are based on many factors including morphology, 
histology, grade as well as gene expression profiles.  The characteristics and molecular classifications of 
these tumors are necessary to properly determine tumor aggression and to choose the best treatment 
option.  Based on gene-cluster analysis, five subtypes have been identified and described for breast 
cancers tumors: Luminal A, Luminal B, Basal-like, Human Epidermal Growth Factor Receptors (HER2) and 
Normal breast-like. [1, 2]  However, the classification of subtypes used for breast cancer cell lines only 
consists of three groups: Luminal, Basal A and Basal B. [3, 4]  The classification differences between cell 
lines and tumor classifications may be due to the absence of stromal and immune gene signatures in cell 
lines.  While the cell line classification does not consist of a HER2 subtype, HER2 overexpression is 
observed in Luminal and Basal A subtypes. [3, 4] 
Table 1 lists the cell lines used, along with various characteristics used in tumor diagnostics, 
which include gene cluster type, along with the presence or absence of the following receptors: 
estrogen, progesterone and HER2.  As can be seen in Table 1, an equal amount of Luminal and Basal cell 
lines were selected in order to have each subtype present during our analyses, as well as the fact that 
each breast cancer cell line has a unique expression profile. 
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1.2. RECEPTORS PRESENT IN BREAST CANCER CELLS  
The presence of cell surface and intracellular receptors in breast cancer is of great importance 
during the diagnostics of breast cancer.  Hormone receptor positive tumors have available targeted 
treatments, which have been proven to be very effective.  Hormone receptors of interest in breast 
cancer are Estrogen Receptor (ER), Progesterone Receptor (PR), HER1 and HER2. 
Table 1: Breast cancer cell lines characteristics (Adapted from Kao, 2009, and Neve, 2006 [3, 4]) 
 
Cell Line Cell Line 
Subtype 
Tumor Type Source Estrogen 
Receptor 
Progesterone 
Receptor 
HER2 
Receptor 
Hs578T Basal B Invasive Ductal 
Carcinoma 
Primary 
Breast 
No No No 
MCF7 Luminal Invasive Ductal 
Carcinoma 
Pleural 
Effusion 
Yes Yes No 
MCF10A Basal B Non-tumorigenic 
Epithelial Cell Line 
Primary 
Breast 
No No No 
MDA-MB-231 Basal B Adenicarcinoma Pleural 
Effusion 
No No No 
MDA-MB-468 Basal A Adenicarcinoma Pleural 
Effusion 
No No No 
SKBR3 Luminal Adenicarcinoma Pleural 
Effusion 
No No Yes 
T47D Luminal Invasive Ductal 
Carcinoma 
Pleural 
Effusion 
Yes Yes No 
ZR-75-1 Luminal Invasive Ductal 
Carcinoma 
Ascites 
Fluid 
Yes No No 
 
1.2.1. Estrogen Receptor 
 
Many physiological processes in humans are influenced by the presence of estrogens.  Estrogens 
mediate their effects through the binding and interactions with the estrogen receptor (ER).[5]  The ER is 
known to be present under two forms, ERα and ERβ, which are encoded by two separate genes, ESR1 
and ESR2, respectively.  These two forms are tissue specific, have similar affinities for steroid ligands, 
and can be both localized to the nucleus, or to the plasma membrane.[6]   
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The development of breast cancer has been shown to be linked to the presence of estrogen.[5]  
Two hypotheses have been suggested to explain this phenomenon.  First, the binding of estrogen to 
intracellular or membrane bound estrogen receptors cause an increase in cell division.  This increase in 
cell proliferation leads to elevated DNA synthesis and therefore an elevated risk of DNA replication 
errors, ultimately leading to cancer development.[5]  The second hypothesis is that estrogen 
metabolism  produces genotoxic metabolites that can cause DNA damage.[5]  
While estrogen receptors are linked to the activation of cancer, there are specific treatments 
that target the ER, called Selective Estrogen Receptor Modulators (SERMs) which include tamoxifen, a 
very effective anti-cancer agent for ER+ cancers.[5]  Another class of treatments that target the ER are 
Selective Estrogen Receptor Modulators (SERDs).  Currently only one SERDs is available for the 
treatment of breast cancer, Faslodex (Fulvestrant).[7, 8] 
1.2.2. Progesterone Receptor 
 
Progesterone is a steroid that is critical to normal breast development, and mediates its effects 
by binding to progesterone receptors (PR).  Two isoforms have been identified for the progesterone 
receptor, PR-A and PR-B.  Both isoforms are synthesized from the same gene, but have different 
translation start sites, creating two receptors of different masses, namely PR-A lacks the 164 N-terminal 
amino acids found in PR-B.[9, 10]  The ratio of isoforms A to B is unknown, but appears to be a crucial 
element in cell homeostasis.[10] 
One single nucleotide polymorphism (+331G/A) has been identified for this receptor, which 
affects the transcriptional activity of the gene, leading to a greater production of the PR-B receptor.  
There are some conflicting studies in whether or not there is a link between this SNP and the presence 
of breast cancer, but overall, there has been no association between this mutation and the risk of 
developing breast cancer.[9]  
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1.2.3. Human Epidermal  Growth Factor Receptor (HER) 
 
The Human Epidermal Growth Factor Receptor is comprised of 4 isoforms, HER1 (also known as 
epidermal growth factor receptor, EGFR), HER2, HER3 and HER4.  These four receptors are encoded by 
the gene ERBB1/2/3/4, respectively.[11]  All four of these receptors have been shown to influence 
tumor development by affecting cell proliferation, migration, angiogenesis and apoptosis protection.[12]  
While no defined ligands are known for the four HER receptors, it is known to play a key role in the 
amplification of cell signaling through a dimerization reaction.  This dimerization has been shown to 
increase receptor-ligand affinity, enhancing its own activation.  The activated receptor promotes the 
phosphorylation of tyrosines in its intracellular domain, which is subsequently recognized by specific 
cytoplasmic signal transducers, which inevitably leads to cell growth and proliferation.[13]  Since these 
receptors cause increase cell proliferation and are capable of preventing apoptosis, their overexpression 
in breast cancer leads to very aggressive tumors.[11]  HER2 has been studied the most due to its 
frequent overexpression in breast cancer, estimated to between 18-25% of human breast cancers, and is 
therefore a targeted receptor.[11, 14]   
The attempt to explain the aggression observed in tumors overexpressing HER2 has been of 
interest.  Ginestier at al. in 2007 demonstrated a strong correlation between ALDH1 overexpression (a 
marker of cancer stem cells, see section 4.3 for more details) and HER2 overexpression.  It is believed 
that the aggression observed in HER2 breast cancers is due to a large population of cancer stem cells, 
where cancer stem cells have been linked to anti-cancer agent resistance. [15] 
While HER2 overexpression is generally undesired due to its aggressive behavior, specific 
treatments targetting this receptor have been developed and have proven to be very effective.  
Treatments include Trastuzumab and Lapatinib, which are specific inhibitors of the HER2 receptor (see 
section 2.1.2.2.2 HER2 Inhibitor for more details).[1, 13, 16-18] 
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1.3. MOLECULAR SUBTYPES 
Molecular subtypes used in the description of breast cancer cell lines and breast cancer tumors 
are slightly different.  In order to better understand how these two classification systems overlap, Kao et 
al looked at the various gene expression patterns of all subtypes to determine how cell lines would be 
classified using the breast cancer tumor subtypes.  It was determined that the Luminal cell lines most 
resembled Luminal A and Luminal B tumors, while Basal A cell lines were most similar to basal-like 
tumors, and Basal B cell lines were similar to basal-like or HER2 overexpressing tumors.[2, 3]  While the 
Basal B cell lines displayed expression patterns that are similar to HER2 overexpressing tumors, Basal B 
cell lines do not overexpress HER2 and are referred to as as triple negative cell lines.[3]  
For breast cancer cell lines, the molecular subtypes are important to take into consideration 
because previous studies have shown that gene expression profiles are dependent on the molecular 
subtype.  Meaning that some genes may demonstrate an overexpression in one molecular subtype, 
whereas a downregulation is observed in others.  Therefore gene expression variations observed may 
simply be due to its cell line characteristics.[3] 
Since each molecular subtype is very different, and requires a different treatment plan, 
molecular subtypes are always determined for breast cancer patients.  Much detail is available for 
breast cancer tumors subtypes; therefore a more comprehensive assessment of these subtypes follows. 
1.3.1. Luminal A 
 
Luminal A cancers originate from the inner cells, called luminal cells, which line the mammary 
duct.[1]  Luminal cells are responsible for the secretion of milk, are highly differentiated and are 
glandular.[19]  Luminal A tumors are mainly characterized by the presence of Estrogen Receptor (ER) 
and, or the Progesterone Receptor (PR, or PgR), but the absence of the Human Epidermal Growth Factor 
Receptor 2 (HER2).  Luminal A cancers have been associated with a good prognosis, where the survival 
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rate is high, and the rate of reccurrence is low because they can be treated with hormone therapies, 
including Tamoxifen.[1, 2, 20]   
1.3.2. Luminal B 
 
Luminal B cancers also originate from the inner cells, called the luminal cells.[1]  While this 
subtype is similar to the Luminal A subtype, where there is the presence of Estrogen Receptor (ER) and, 
or the Progesterone Receptor (PR, or PgR), Luminal B tumors often express the HER2 receptor. [1, 2, 21, 
22]  Hormone treatments are available; however because of the presence of the HER2 receptor, Luminal 
B tumors tend to have a higher tumor grade, and exhibit high proliferation rates and DNA amplifications, 
and therefore are associated with a poor prognosis.[1-3] 
Treatments of Luminal B tumors include hormone therapy, Trastuzumab-based, chemotherapy 
and/or surgery.[1] 
1.3.3. Basal-Like 
 
Basal-like cancers originate from the outer cells, called the basal cells (myoepithelial), which line 
the mammary duct [1, 3].  Basal cells do not have a role in secretion, but rather in muscle contraction, 
and are undifferentiated.[19]  These tumors are often associated with the hereditary BRCA1 breast 
cancer tumors and have been known to be the most aggressive subtype. [1]  Most Basal-like tumors are 
negative for all three receptors, and are commonly referred to as the Triple Negative tumor (TN).  
However, this is not always the case.  It is estimated that 5-45% of basal tumors are ER+ and that 14% 
are HER2+.[1, 17]  For patients diagnosed with a tumor that is both basal-like and TN, the prognosis 
tends to be very poor because of the lack of targeted treatment (such that are available for hormone 
responsive tumors) and because the cancer is very aggressive.[1]  
Stem cells, or cells with stem cell like properties are believed to be the source of basal-like 
cancers.  There have been reports showing that the Basal phenotype are largely composed of the 
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CD44+/CD24- polulation, otherwise known as a Cancer Stem Cell population (see section 4.3 for more 
details).[4]  The expression of markers such as cytokeratins (specifically CK5/6, 14 and 17) and the 
transcription factor p63 are found in basal-like breast cancers.[23] 
Treatment options for Basal-Like tumors depend on the presence of receptor overexpression.  If 
ER, PR or HER2 is overexpressed, hormone, or trastuzumab treatments are used.  For TN tumors, 
treatment options include chemotherapy and surgery.[1] 
1.3.4. HER2 overexpressing 
 
HER2 overexpression has been linked to mammary tumorigenesis, tumor aggression and 
metastasis and therefore tends to have a poor prognosis.[14]  HER2+ tumors are negative for both ER 
and PR, while they overexpress the HER2 receptor.  While the tumor is known to be aggressive, targeted 
treatments for HER2 positive breast cancers are available.  Trastuzumab (or Herceptin®), and Lapatinib 
are two targeted treatments for HER2 positive tumors that have proven to be very effective.[1, 13, 16-
18, 24] 
1.3.5. Normal breast-like 
 
The normal breast-like cancers are cancers which do not fit within the other predefined 
subtypes.[1]  This subtype has been shown to demonstrate similar expression patterns as a normal 
breast tissue. [3]  Overall, these tumours are small, and usually have a good prognosis.[1] 
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2. ANTI-CANCER AGENTS 
Anti-cancer agents, such as chemotherapy and targeted treatments, are used in the treatment 
of breast cancer.  However, some patients experience resistance to these treatments, which inevitably 
ends in treatment failure.  Research has shown that the presence of breast cancer stem cell, as well as 
proteins involved in drug bioavailability, such as membrane transporters and drug metabolizing 
enzymes, are the sources of resistance (see Section 4 for more details).  Our focus is on the effects of the 
Phase I drug metabolizing enzymes, Cytochrome P450s on the bioavailability of anti-cancer agents.  First 
the agents used in breast cancer will be described. 
2.1. TYPES OF TREATMENTS 
Two main groups of treatments are used in the treatment of breast cancer, chemotherapy 
agents, and targeted treatments.  Different classes of each group are available; however, chemotherapy 
agents destroy all quickly dividing cells, whereas targeted treatments attack cells which overexpress 
specific proteins or processes observed in breast cancer cells. 
2.1.1. Chemotherapy Classes 
 
Chemotherapy is the process where anticancer medications are used to treat cancer.  The goal 
of chemotherapy agents is to prevent the growth and spreading of cancer cells by interfering with 
normal cell processes at different points.  Some chemotherapy agents mechanism of action occurs at 
the genetic level (DNA and RNA damage), while other interfere with normal protein function.[25]  
Chemotherapy agents have been categorized in different chemotherapy classes based on their 
mechanism of action.  These classes include alkylating agents, anti-metabolites, plant alkaloids (vinca 
alkaloids and Taxanes), Topoisomerase inhibitors and cytotoxic antibiotics (anthracylines).  See Table 2 
for more details on chemotherapy agents used in breast cancer treatments.  
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Table 2: List of chemotherapy agent classes used for breast cancer and their mechanism of action 
 
Chemotherapy 
Classes 
Action Mechanism Examples used in breast cancer 
Alkylating Agents DNA damage through alkylating nucleophilic 
sites of DNA bases. [26] 
Cyclophosphamide and carboplatin 
Anti-metabolites DNA and RNA damage through masquerading 
as pyrimidine and purine bases. [27] 
Methotrexate, 5-fluorouracil, 
Gemcitabine and Capecitabine 
Plant Alkaloids Microtubule binding [27, 28] Vinca Alkaloids and Taxanes 
Vinca Alkaloids Natural product that destabilizes microtubule 
by binding to the β-subunit of tubulin 
destroying mitotic spindles and blocks mitosis. 
[27, 28] 
Vinblastine and Vinorelbine 
Taxanes Natural product that stabilizes microtubule by 
binding to the β-subunit of tubulin inhibiting 
depolymerisation and slowing down mitosis. 
[27, 28] 
Paclitaxel and Docetaxel 
Topoisomerase 
inhibitors 
Relaxes DNA supercoiling by Topoisomerases, 
causing DNA vulnerability to intercalating 
agents.[29] 
Irinotecan (TOP1) and 
Anthracyclines (TOP2); currently in 
clinical trials. 
Cytotoxic antibiotics 
-Anthracyclines 
Intercalating agents, that inhibit 
topoisomerases and generated reactive 
oxygen species.[30] 
Doxorubicin and Epirubicin[31] 
 
2.1.2. Targeted Treatments 
 
Targeted treatments are often used in the treatment of breast cancer, specifically cancers that 
are receptor positive.  Treatment groups include hormone therapies and specific targeted enzymes. 
2.1.2.1. Hormone Therapy 
 
The majority of breast cancer tumors are hormone receptor positive and therefore can benefit 
from hormone therapies.  Hormone receptors, namely estrogen and progesterone receptors, respond to 
intra- and extracellular hormone levels, which act as a signal to turn on cell growth.  Therefore, hormone 
therapies work by blocking the hormone action potential at their specific receptors, as well as to lower 
the amount of hormone in the body.[7]  Hormone therapies include aromatase inhibitors, Selective 
Estrogen Receptor Modulators and Estrogen Receptor Downregulators. 
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2.1.2.1.1. Aromatase inhibitors 
 
Aromatase, otherwise known as CYP19A1, is an enzyme which catalyzes the conversion of the 
hormone androgen to estrogen. [32, 33]  Aromatase Inhibitors are molecules that inhibit aromatase 
activity by blocking the production of estrogen in the body (through CYP19A1 activity).  These inhibitors 
only work in post-menopausal women, who are diagnosed with ER+ cancers, because pre-menopausal 
women produce significant amounts of estrogen in the ovaries without aromatase activity.[34]   
Aromatase inhibitors include Anastrozole, Exemestane and Letrozole.[7, 34] 
2.1.2.1.2. Selective Estrogen Recetor Modulators (SERMs) 
 
Selective Estrogen Receptor Modulators (SERMs) work by competitively binding to the active 
site of Estrogen Receptors.  Since estrogen is unable to bind to the estrogen receptor in the presence of 
SERMs, the breast cancer cell does not receive a signal to grow and divide, and therefore the 
proliferation of breast cancer is blocked.[35]  SERMs include Tamoxifen, Raloxifene and Toremifen.[7] 
2.1.2.1.3. Seletive Estrogen Receptor Downregulators (SERDs) 
 
Selective Estrogen Receptor Downregulators (ERDs) have a similar action mechanism as SERMs, 
however, they also work to reduce the amount of Estrogen receptors in the breast cell, and change the 
shape of the Estrogen Receptor active site, so that the receptor cannot recognize the hormone as 
efficiently.[8]  Currently there is only one SERDs commercially available, Faslodex (Fulvestrant).[7, 8] 
2.1.2.2. Specific Targeted Enzymes 
 
Certain enzymes or receptors are overexpressed in breast cancer.  By blocking the activity of 
these specific enzymes, the proliferation rate of cancer cells is blocked.  These enzymes include the 
Epidermal Growth Factor Receptor, HER2 and VEGFR (enzyme responsible for angiogenesis). 
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2.1.2.2.1. Human Epidermal Growth Factor Receptor (HER) Inhibitor 
 
The Human Epidermal Growth Factor Receptor (HER) is a family of receptors which play a key 
role in the development and proliferation of cancer as well as in the prevention of apoptosis.[12-14]    
The HER family is known to require tyrosine kinase activitation.  In breast cancer, HER1, also known as 
the epidermal growth factor receptor (EGFR) and HER2 are most often studied members of the HER 
family, where HER2 is considered to be the most important because of its frequent overexpressed 
breast cancer.  Several molecules have been used to inhibit this family of receptors.  Gefitinib is an EGFR 
inhibitor that blocks the kinase activity of the EGFR receptor, however it is not approved for breast 
cancer.[36]  Lapatinib (Tykerb®) is a small molecule which inhibits the tyrosine kinase of both the HER1 
and HER2 receptors.[36]  Finally, Trastuzumab (Herceptin®) is a monoclonal antibody which specifically 
recognizes the HER2 receptor. 
2.1.2.2.2. Angiogenesis Inhibitors 
 
The vascular endothelial growth factor receptor (VEGFR) is responsible for the development and 
maintenance of tumor vasculature, or angiogenesis through a signal transduction process. [37] When 
the vascular endothelial growth factor (VEGF) binds to its receptor, VEGFR, signals are sent to initiate 
the growth of new blood vessels and to promote the maintenance of old ones.  This is a vital process to 
all cells, and has been seen to be overexpressed in some tumors.  This process has also been suggested 
as a possible source of cancer metastasis.  Therefore, by targeting angiogenesis, cells which overexpress 
VEGF, such as cancer cells, would be most affected by angiogenesis inhibitors.  Several treatments are 
available and include: monoclonal antibodies that binds specifically to VEGF, Bevacizumab (no longer 
approved for the treatment of breast cancer), small-molecule inhibitors of tyrosine kinase, Axitinib (not 
yet approved in Canada), Sunitinib, Sorafenib, as well as endogenous inhibitors of angiogenesis, 
Endostatin and Angiostatin. [36, 38-40]  Currently no Angiogenesis inhibitors are approved for the 
treatment of breast cancer. 
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Table 3: List of hormonal and targeted treatment classes used for breast cancer and their mechanisms of 
action 
 
Chemotherapy Classes Action Mechanism Examples used in breast cancer 
Aromatase Inhibitors Reduction of estrogen 
production through the 
inhibition of aromatase activity 
(through CYP19A1) [32, 33] 
Anastrozole, Exemestane and 
letrozole [7, 34] 
Selective Estrogen Receptor 
Modulators (SERMs) 
SERMs bind to the ER preventing 
the growth signal of ER+ breast 
cancer to grow and divide. [35] 
Tamoxifen, Raloxifen and 
Toremifen [7] 
Selective Estrogen Receptor 
Downregulators (SERDs) 
Reduction of the amount of ER 
present, and change in the active 
site shape to reduce hormone 
binding efficiency. [8] 
Faslodex [7, 8] 
Human Epidermal Growth Factor 
Receptor (HER) Inhibitors 
Inhibition of HER to prevent 
receptor activation which allow 
for the apoptosis of cancer 
cells.[12-14] 
Gefitinib (not approved for 
breast cancer) Trastuzuab and 
Lapatinib [13, 36] 
Angiogenesis Inhibitors Blocking of VEGFR to reduce 
blood flow to tumors by 
reducing the formation of new 
blood vessel formation and 
maintenance of old vessels. [37] 
Axitinib (not yet approved in 
Canada), Bevacizumab (no 
longer approved for breast 
cancer), Sunitinib, Sorafenib, 
Endostatin and Angiostatin (not 
yet approved) [36, 38, 39] 
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2.2. METABOLISM 
The clearance of chemotherapeutics is an essential aspect to consider for drug administration.  
Many of the chemotherapy agents used in the treatment of breast cancer are known substrates and or 
inhibitors of the superfamily of metabolizing enzymes called Cytochrome P450 (CYP450s).  Table 3 lists 
the various anti-cancer agents used in the treatment of breast cancer, along with the CYP450s isoforms 
that are responsible for their clearance.  As can be seen, some agents are not metabolized by CYP450s 
and therefore may require other pathways for drug clearance, such as by drug transporters. 
Table 4: Anticancer agents used in the treatment of breast cancer, and their metabolism by CYP450s 
 
Anti-Cancer Agent CYP450 
Cyclophosphamide  CYP2B6, 2A6, 3A4/5, 2C8,2C9, 2C19 [41-44] 
Carboplatin None[42-44] 
Methotrexate None [43] 
5-fluorouracil Inhibitor of CYP2C9 [45] 
Gemcitabine None 
Capecitabine None 
Vinblastine CYP3A4 [44] 
Vinorelbine CYP3A4 [44, 46, 47] 
Paclitaxel CYP2C8, 3A4, 3A5 [41, 43, 44]  
Docetaxel CYP3A4/5 [43, 44, 48] 
Doxorubicin Inhibitor of CYP2D6 [45] 
Epirubicin None [43] 
Anastrozole CYP3A4/5 [44, 49] 
Exemestane CYP3A4 [44, 50] 
Letrozole CYP2A6 and 3A [44, 51] 
Tamoxifen CYP1A1/2, 1B1, 2B6, 2C9/19, 2D6, 2J2 3A4/5 [44, 45, 52-55]  
Raloxifene Inhibitor of and metabolism by CYP3A4[56-58] 
Toremifene CYP3A4 [44, 59] 
Fulvestrant None 
Gefitinib CYP3A4, 2D6, minor 3A5 and 1A1 [60] 
Trastuzumab None 
Lapatinib CYP3A4/5 and minor by 2C8/19 [12, 60] 
Bevacizumab None 
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3. CYTOCHROME P450S 
Cytochrome P450s (CYP450) are enzymes which have been shown to be involved in the 
bioavailability of anti-cancer agents through phase I metabolism.  Each CYP450 has a specific role in drug 
metabolism and tissue localization pattern.  CYP450 isoforms which are locally expressed in breast 
cancer tissue and breast cancer cell lines are of interest because they may play an important role in the 
local drug metabolism of various anti-cancer agents. 
3.1. DESCRIPTION 
Drug metabolism, an important role in drug disposition, is executed by many enzymes in the 
human body, but more specifically in the liver.  The most important family of enzymes responsible for 
the metabolism of medications is the cytochrome P450 (CYP450) superfamily.  These enzymes work to 
detoxify the body of many xenobiotic molecules through a biotransformation reaction, rendering the 
molecule more hydrosoluble.  This in turn facilitates the secretion of xenobiotics into urine and bile. [61]  
In human, this superfamily is composed of 57 known CYP450 genes, which are classified into families 
and subfamilies, depending on sequence homology. [62, 63]   Isoforms which display greater than 40% 
homology are grouped within the same family, while enzymes with greater than 55% are classified 
within the same subfamily.[64, 65]  Each CYP450 isoform has various roles in metabolism and in the 
synthesis of molecules, where similar functions are common within the same family. 
  While CYP450s localized in the liver play a major role in drug metabolism, either in drug 
clearance or in the activation off pro-drugs, extrahepatic CYP450s are implicated in both local drug 
metabolism, as well as in the synthesis and degradation of endogenous molecules, such as steroids, and 
fatty acids. [32, 33, 45, 63, 66-70] 
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3.1.1. Structure 
 
All isoforms of the CYP450 superfamily are relatively small proteins with molecular weights 
ranging between 45 and 66 kDa.[71]  CYP450s are found in every tissue at varying concentrations, and 
are all membrane bound protein located in the endoplasmic reticulum.[72]  All CYP450s contain a 
ferroprotoporphyrin IX heme group, which constitutes the active site (the heme moiety).  However, the 
specificity of each isoform is dependent upon the apoprotein and not the active site.  [65]   
In order for CYP450s to oxidize a molecule, these isoenzymes require two things; the presence 
of an energy source, which in the case of CYP450s is the reducing agent, nicotinamide adenine 
dinucleotide phosphate (NADPH), as well as atmospheric oxygen.[65]   
3.1.1.1. Oxydation Cycle 
 
The oxidation cycle of CYP450s has been well described, and is summarized and simplified in 
Figure 1. [73]  Overall, the cycle is described as a dynamic process, which means that these steps do not 
necessarily occur in a sequential fashion. [73]  In brief, a substrate binds to the active site in a reversible 
fashion.  Using NADPH, the heme centre is reduced from the ferric state (Fe3+) to the ferrous state (Fe2+).  
One molecule of oxygen then binds generating a ferrous CYP-Substrate complex.  The oxygen molecule 
is then cleaved by using a second electron (either from another molecule of NADPH or by Cytochrome 
b5.  The molecule is then oxidized and released from the active site.[65]  In the end, the iron is returned 
to the ferric state, and is ready for another cycle of oxidation. 
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Figure 1: Oxydation cycle of CYP450s.  (Adapted from Guengerich, 2007 [73]) 
 
3.2. FAMILIES 
Cytochrome P450 isoforms are grouped according to their families and subfamilies.  In human, 
the CYP450s are grouped into 18 families, and 43 subfamilies.[74, 75]  Not all families have been shown 
to be influenced in drug metabolism or steroid biosynthesis; therefore specific CYP450s were selected 
based on their role in drug metabolism, steroid metabolism, or link to breast cancer.  Below is a table of 
all CYP450s analyzed, categorized by their families, and describing their roles and localization in human. 
3.3. ROLES OF CYP450S 
3.3.1. Systemic Metabolism (Exogenous molecules) 
 
Hepatic CYP450 isoforms have been well characterized.  These enzymes account for ~75% of the 
drug metabolizing enzymes found in the liver.  The five most abundant hepatic CYP450s, accounting for 
95% of hepatic metabolism are CYP3A4, 2D6, 1A2, 2C9 and 2C19, where 3A4 is the most important.[73] 
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Table 5: Table of CYP450s of interest describing their roles and localization 
 
Family Subfamily Enzymes Roles Localization 
CYP1 CYP1A CYP1A1 Hydroxylation of Steroids and Xenobiotic 
metabolism [63, 66-69] 
Hepatic[73] 
CYP1A2 Hydroxylation of Steroids and Xenobiotic 
metabolism [63, 66-69] 
Hepatic[73] 
CYP1B CYP1B1 Detoxification of steroidal hormones, 
therapeutic drugs and environmental toxins [76] 
Adrenal glands, ovary, testis, 
lung, prostate[72] 
CYP2 CYP2A CYP2A6 Xenobiotics Metabolism[63] Hepatic [77] 
CYP2B CYP2B6 Xenobiotics Metabolism[63] Hepatic[73] 
CYP2C CYP2C8 Xenobiotics Metabolism[63] Liver, kidney, adrenal gland, 
brain, uterus, breast, ovary and 
duodenum[78] 
CYP2C9 Xenobiotics Metabolism[63] Hepatic[73] 
CYP2C19 Xenobiotics Metabolism[63] Hepatic[73] 
CYP2D CYP2D6 Xenobiotics Metabolism[63] Hepatic[73] 
CYP2E CYP2E1 Xenobiotics Metabolism (Ethanol)[45, 63] Hepatic[73] 
CYP2J CYP2J2 Fatty Acid and xenobiotic Metabolism [53, 63] Heart, kidney, lung [72, 79, 80] 
CYP2W CYP2W1 Procarcinogens [81] Prostate, pancreas, placenta, 
lung, colon, intestine[63, 82] 
CYP3 CYP3A CYP3A4 Xenobiotics Metabolism[63] Hepatic[73] 
CYP3A5 Xenobiotics Metabolism[63] Hepatic, lung, small intestine, 
prostate[83] 
CYP3A7 Xenobiotics Metabolism[63] Prenatal Tissue (liver) [65, 84] 
CYP4 CYP4A CYP4A11 Fatty Acid Metabolism[63] Kidney and liver[72] 
CYP4Z1 Lauric Acid Metabolism[70] Breast, breast carcinoma, kidney 
and liver[63, 82, 85] 
CYP17 CYP17A CYP17A1 Androstenedione synthesis[33, 67] Adrenal cortex[72] 
CYP19 CYP19A CYP19A1 Aromatase Activity[32, 33] Breast Brain, placenta 
gonads[33, 72] 
 
3.3.2. Local Metabolism (Exogenous molecules) 
 
The local metabolism of exogenous molecules by various Cytochrome P450 isoforms has 
become of greater importance.  The presence of many CYP450 enzymes has been identified in extra-
hepatic tissues, such as the intestines, kidneys, brain, lungs and heart. [86-92] While concentrations of 
these enzymes may be inferior to those found in the liver, their implications in drug disposition cannot 
be ignored.  Above all, the expression of the CYP450 isoforms appear to be tissue specific, where many 
isoforms identified in the extra-hepatic tissues are not found in the liver.  For example, the mRNA 
expression of CYP2J2, an isoform not present in the liver, has been identified in abundance in cardiac 
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tissue.[79]  Since many extra-hepatic CYP450s are not evaluated during the drug discovery process, the 
metabolism potential of these tissue specific CYP450s are unknown, and could locally metabolize 
exogenous molecules.  As is seen in the liver, inter-subject variability is observed in the expression of 
CYP450s, and therefore, this same variability could be present in other tissues, such as the heart, or 
breast.    This inter-subject variability may be another source of variation in drug effect.   
3.3.3. Synthesis of endogenous molecules 
 
The presence of steroids in breast cancer has been shown to be important, especially in hormone 
receptor positive breast cancers.  Therefore, the expression of various CYP450s responsible for the 
synthesis and degradation of steroids expressed in breast cancer could be of great importance.  The 
members of the Family 1 isoforms, namely CYP1A1, 1A2 and 1B1, have been shown to play a role in the 
hydroxylation of progesterone, testosterone and estrogen.[66-69] Therefore the local expression of 
these three isoforms may lead to the growth and proliferation of breast cancers which are stimulated by 
the presence of these hormones, (namely ER+ cancers being stimulated by estrogens).  The expression 
of two other CYP450 isoforms which may be of interest in breast cancer are  CYP17A1, mainly expressed 
in prostate tissue and 19A1, mainly expressed in breast tissue.  CYP17A1 plays a role in the conversion of 
pregnenolone to androstenedione, wherease CYP19A1 converts androstendione to estrone through the 
use of aromatase activity.[33, 67, 93]  Therefore the presence of these five CYP450s may be greatly 
implicated in the local synthesis of estrogens and other steroids. 
3.3.4. Adverse Drug Events/Drug-Drug Interactions 
 
Adverse drug events (ADEs) are events where an injury occurs from the use of a medication 
when the drug has been administered at a normal dose.   ADE can lead to toxicity or loss of treatment 
efficiency, and can occur due to genetic alterations (such as polymorphisms), drug-drug interactions, or 
food-drug interactions.  Overall, ADE results in 6.7% of hospitalizations in the United States, which has 
been estimated to cost 1.5 million dollars. [94, 95]  
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Drug-drug interactions (DDIs) are highly studied ADE, where interactions with the major hepatic 
CYP450s, such as CYP3A4 and 2D6 are commonly evaluated (substrates, inhibitors or inducers of these 
enzymes).[73]  One example of a DDI for ER+ breast cancer patients would be the co-administration of 
tamoxifen, a substrate of CYP2D6, and the anti-depressant fluoxetine, a substrate of CYP2D6.[45, 52, 96] 
Under this situation, tamoxifen, which requires metabolism by CYP2D6 to become endoxifen, its active 
form, would be affected by the presence of the anti-depressant, due to competitive inhibitions of the 
enzyme.  Therefore, a lack of active metabolite would be present, and a treatment failure would ensue.  
Overall, DDI need to be avoided in all patients to ensure that no toxicity or treatment failure 
occurs. 
3.4. IMPORTANCE IN BREAST CANCER  
Two CYP450 Isoforms have been identified, through this work, to be highly expressed in the 
breast cancer cell lines analyzed: CYP1B1 and CYP2J2 (See Chapter 4 for more details).  Both isoforms 
have a different role and importance in metabolic reactions, where 1B1 is involved in hormone and toxin 
detoxification, while 2J2 is involved in the hydroxylation of fatty acids. [63, 76] 
3.4.1. CYP1B1 
 
The expression of CYP1B1, a 58 kDa protein, has been found in many extra-hepatic tissues such 
as the uterus, ovaries, testis, prostate and adrenal glands.[97, 98]  CYP1B1 has been shown to catalyze 
the hydroxylation of 17β-estradiol and testosterone.[99]  However, CYP1B1s metabolic activity has also 
been linked to the activation of several pre-carcinogenic molecules such as benzanthracene, 
benzo(a)pyrine, DMBA, 1-ethynyl-pyrene, 3-methyl-cholantrene and oestradiol.[97]  Since an 
overexpression of this isoforms has been found in tumors, such as in breast cancer, it is believed that 
CYP1B1 may be a source of steroid hormone-mediated cancer.[99, 100]   
 
 
22 
 
In order to understand the local metabolism potential of CYP1B1 in breast cancer cells, 
7-ethoxyresorufin, a substrate which is common to CYP1A1, 1B1 and 1A2, may be used.[101]  The rate 
of metabolism of 7-ethoxyresorufin is quite different in each of these enzymes.  The maximum activity 
observed in CYP1A1 is greater than what is observed by CYP1B1, however, the substrate demonstrates a 
stronger affinity towards CYP1B1 than 1A1 (lower Km for 1B1).[101]  However, since CYP1B1 is 
preferentially expressed in breast cancer cell lines, the metabolic activity of 7-ethoxyresorufin 
corresponds to CYP1B1 expression. 
3.4.1.1. Homology 
 
CYP1B1 shares a strong homology with the two other members of the CYP1 family, CYP1A1 and 
1A2.  According to sequence alignment, CYP1B1 shares 39% and 37% homology with CYP1A1 and 1A2, 
respectively.  The active site is where the most homology is seen where many of the amino acids are 
conserved; this leads to large substrate overlap.[102]   However, there are small differences in the 
amino acids in the active site which leads to substrate affinity differences (see figure 2). 
 
 
Figure 2: Active site of CYP1A1 (green), 1A2 (blue) and 1B1 (red).  7-Ethoxyresorufin is shown in the 
active site. (Adapted from Takemura, 2010.[102]) 
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3.4.1.2. Polymorphisms in CYP1B1 
 
There are many known Single Nucleotide Polymorphisms (SNPs) for CYP1B1, both in the coding 
and non-coding regions.  Some of these SNPS have been further characterized and have been given 
specific variant names (see Table 5).  As can be seen, many of the CYP1B1 variants do not lead to altered 
metabolic activity with the exception of variant *6 and *7 which demonstrate a significant decrease in 
enzyme efficiency.[103]  This finding was of interest because *6 and *7 variants are a combination of 3 
and 4 SNPs, respectively, and when only one or two of these mutations are present, no change in 
enzyme activity was observed.  Therefore it is hypothesized that only in the presence of all three SNPs 
(found in *6 and *7 variants), a change in protein folding results in a conformational change of the 
enzymes active site.[103]  Others have reported that the *2 and *3 variants have a 2-4 increase in 
metabolic activity and an increased risk of developing certain types of cancers.[76]  Since CYP1B1 has 
been linked to activation of certain pre-carcinogenic molecules, it is believed that an increased activity 
of CYP1B1 may lead to a greater production of carcinogens, and hence cancer development, specifically 
in tissues where elevated expression of CYP1B1 is found.[76] 
Table 6: Known polymorphisms of CYP1B1 and their effects on metabolic activity (Adapted from Aklillu, 
2001, [103]) 
 
Variant Nucleotide Change Amino Acid Substitution Protein Activity 
CYP1B1*1 None None Wild Type Activity 
CYP1B1*2 142C>G, 355G>T Arg48Gly, Ala119Ser Lower expression level, similar kinetic 
activity as wild type 
CYP1B1*3 1294C>G Leu432Val Lower expression level, similar kinetic 
activity as wild type 
CYP1B1*4 1328A>G Asn453Ser Lower expression level, similar kinetic 
activity as wild type 
CYP1B1*5 142C>G, 1294C>G Arg48Gly, Leu432Val Unknown 
CYP1B1*6 142C>G, 355G>T, 
1294C>G 
Arg48Gly, Ala119Ser, 
Leu432Val 
Similar expression level, kinetic 
activity significantly lower 
CYP1B1*7 142C>G, 355G>T, 
1294C>G, 1328C>G 
Arg48Gly, Ala119Ser, 
Leu432Val, Ala443Gly 
Lower expression level, kinetic activity 
significantly lower 
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3.4.2. CYP2J2 
 
CYP2J2, a 56 kDa protein, is localized primarily in the heart, kidneys, lungs and breast.  [72, 79, 
80]  CYP2J2 has been shown to be involved in the metabolism of endogenous molecules, such as fatty 
acids, arachidonic and linoleic acid, as well as xenobiotic molecules such as ebastine, terfenadine, 
astemizole, amiodarone, albendazole, danazol, thioridazine, tamoxifen, cyclosporin A, nabumetone and 
mesoridazine. [53, 63, 104-106]  Substrate overlap has been observed between CYP2J2 and 3A4, 
because both isoforms have large active sites.  However, because CYP2J2 has a slightly more cylindrical 
and narrow active site, substrates are more restricted and therefore can only be metabolized at a single 
site.[53]  This restriction leads to differences in regioselectivity between CYP2J2 and 3A4.[107] Figure 3 
shows the active site of CYP2J2 where ebastine has been shown in place. 
In order to understand the metabolism of CYP2J2, ebastine can be used.  While CYP3A4 can 
metabolize ebastine, a different metabolite is formed by CYP3A4 (namely N-desmethyl-ebastine) than 
by CYP2J2 (namely Hydroxyebastine).[106]  In addition, the expression of CYP3A4 mRNAs is almost non-
detectable in breast cancer cell lines, so that the metabolism of ebastine within these cells is specific to 
CYP2J2. 
 
3.4.2.1. Polymorphisms in CYP2J2 
 
There are many known Single Nucleotide Polymorphisms (SNPs) for CYP2J2, both in the coding 
and non-coding regions.  Some of these SNPS have been further characterized and have been given 
specific variant names (see Table 6).  Significant loss in activity has been observed for variant *2, *3 and 
*6 in the metabolism of arachidonic acid and linolein acid, while *4 only showed a loss of function for 
arachidonic acid metabolism, and *5 showed no loss in functional activity. [108, 109]  Variants *8 and *9 
were analyzed using astemizole and ebastine as metabolites, where *8 showed almost a complete loss 
of function, while *9 showed wild type activity. [109, 110]   
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Since CYP2J2 has been shown to be capable of metabolizing xenobiotics, such as tamoxifen, an 
anti-cancer agent, the loss of function of this isoform, which is highly expressed in breast cancer cells, 
may have important implications on local drug metabolism.[53] 
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Ile376
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Figure 3: Active site of CYP2J2 (red).  Ebastine is shown in the active site. (Adapted from Lafite, 
2007.[111]) 
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Table 7: Known polymorphisms of CYP2J2 and their effects on metabolic activity 
 
Variant Nucleotide Change Amino Acid Substitution Protein Activity 
CYP2J2*1 None None Wild Type Activity 
CYP2J2*2 427A>G Thr143Ala Significant decreased in metabolism of 
arachidonic and linoleic acid [108, 109] 
CYP2J2*3 472C>T Arg158Cys Significant decrease in metabolism of 
arachidonic and linoleic acid [108, 109] 
CYP2J2*4 575T>A Ile192Asn Significant decrease in metabolism of 
arachidonic acid, but no difference of 
linoleic acid [108, 109] 
CYP2J2*5 1024G>A Asp342Asn Wild Type activity for arachidonnic and 
linoleic acid [108, 109] 
CYP2J2*6 1210A>T Asn404Tyr Almost complete loss of metabolism for 
arachidonic and linoleic acid [108, 109] 
CYP2J2*7 -50G>T Promotor Decreased promotor activity [109, 112] 
CYP2J2*8 934G>A Gly312Arg Almost complete loss of catalytic activity 
for Astemizole and Ebastine [109, 110] 
CYP2J2*9 1052C>T Pro351Leu Wild type activity for Astemizole and 
Ebastine [109, 110] 
CYP2J2*10[109] 434C>T Pro155Leu No determined 
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4. ANTI-CANCER RESISTANCE 
Several types of cancer cells have shown an innate or acute resistance to anti-cancer agents 
which in turn causes a failure in treatment.  Even though our work has been focussed on metabolic 
factors that could affect anti-cancer resistance, it is also important to acknowledge other sources of 
resistance, such as the impact of membrane transporters on drug bioavailability, as well as the presence 
of Tumor-Initiating cells (T-ICs) and Cancer Stem Cells (CSCs). [113, 114] 
4.1. DRUG BIOAVAILABILITY-MEMBRANE TRANSPORTERS 
Many anti-cancer agents are known substrates of the membrane transporters, Multidrug 
Resistance Protein 2 (MRP2 encoded by the gene ABCC2), Breast Cancer Resistance Protein (BCRP 
encoded by the gene ABCG2) and P-glycoprotein (P-gp, encoded by the gene ABCB1), which are 
responsible for the efflux of these medications.  Table 7 lists the efflux transporters responsible for the 
efflux of anti-cancer agents used in the treatment of breast cancer. [43, 44, 114-119]  These three 
transporters, MRP2, BCRP and P-gp, are highly expressed in the liver membrane, specifically the 
cannulicular side.  Therefore the bioavailability of anti-cancer agents, which are substrates of these 
transporters, will be greatly affected by the presence of these transporters.   
However, these transporters are also present on the basolateral membrane of other tissues, 
acting as efflux transporters, where an elevated expression of BCRP is observed in breast cancer. [115, 
120, 121]  Some studies have shown that an overexpression of membrane transporters occurs when 
cells are treated with anti-cancer agents.  One particular study treated the breast cancer cell line, MCF-7 
with Adriamycin, and demonstrated that an overexpression of P-gp was present in MCF-7-Adriamycin 
resistant cells. [122] Other studies demonstrated an overexpression of BCRP in mitoxantrone resistant 
cells while VP-16 resistant cells overexpressed MRP transporters. [121, 123] Therefore, cancer cells are 
either upregulating their expressions of specific membrane transporters to reduce intracellular exposure 
to anti-cancer agents, or some cancer cells naturally have an overexpression of the specific membrane 
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transporters which aid in their resistance, resulting in a population selection.  In either case, membrane 
transporters are locally expressed in breast cancer, which results in a resistance to anti-cancer agents. 
Table 8: Anticancer agents used in the treatment of breast cancer, and transport by membrane efflux 
transporters 
 
Anti-Cancer Agent Efflux Transporters 
Carboplatin MRP2 [43] 
Docetaxel MRP2 and P-gp [43, 44, 114, 117] 
Doxorubicin MRP2, BCRP and P-gp [43, 44, 115-117] 
Epirubicin MRP2, BCRP and P-gp [43, 115, 116] 
Gefitinib BCRP [115] 
Methotrexate MRP2 and BCRP [43, 115, 116] 
Paclitaxel P-gp [43, 44, 117] 
Raloxifene P-gp and MRP2 [58, 118] 
Tamoxifen P-gp and BCRP [44, 115] 
Toremifene BCRP [115] 
Vinblastine MRP2, P-gp [44, 117] 
Vinorelbine P-gp [119] 
 
4.2. STOCHASTIC CELL THEORY AND TUMOR-INITIATING CELLS 
Stochastic cell theory states that every cell has the potential of becoming a tumor-initiating cell 
(T-IC).  However, this property is not present in every cell, and the chance of developing this property is 
very low.[113]  Therefore, only a small population of cells within a tumor are able to initiate tumor 
growth.[113]  It is believed that the cause of the tumor-initiation process is due to random mutations 
and subsequent clonal selection.[124]  However, this process leads to the production of a homogenous 
tumor.[113] 
The stochastic theory states that T-ICs are resistant to chemotherapy agents and will ultimately 
lead to the relapse of cancer.  However, because it is impossible to predict which cells are T-ICs, and 
they cannot be separated from non-T-ICs, T-ICs cannot be targeted to prevent relapses.[113]  It is also 
unclear as to why T-ICs have developed a resistance to chemotherapy agents. 
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4.3. CANCER STEM CELL THEORY 
The cancer stem cell (CSC) theory states that all tissues are derived from organ-specific stem 
cells.  These cells have the capacity of self-renewal and differentiation, which ensures tissue integrity.  
The CSC hypothesis states that cancer develops from normal stem cells that have undergone oncogenic 
transformation.[124]  Since stem cells are believed to be long living, slow dividing cells, they have a 
longer period of toxin exposure than regular cells, ultimately leading to the development of cancer and 
cancer stem cells.[125]  Since stem cells have the properties of self renewal and differentiation, the 
expansion of the cell population can then lead to additional genetic and epigenetic changes.[124]  In the 
breast, it is believed that the differentiation of CSC is limited to specific cell types, and therefore leads to 
the development of specific breast cancer molecular subtypes.[124] 
4.3.1. Isolation of Cancer Stem Cells 
 
Several methodologies for the isolation and purification of CSC have been suggested: dye 
exclusion (side population), cell culture selection through tumorospheres, cell surface marker 
(CD44+/CD24-/low), and an enzymatic assay for ALDH+ cells (ALDEFLUOR assay).[15, 124, 126, 127]  The 
two most commonly used methods for the isolation of CSC are the cell surface markers and the 
ALDEFLUOR enzymatic assay.   
4.3.1.1. CD44+/CD24-/low 
 
CD44 and CD24 are cell surface markers that are often present in breast cancer cells.  Cells 
which express CD44, but do not express CD24 have been described as being highly resistant to 
chemotherapy agents.  Previous studies showed that placing MCF-7 cells in the presence of 
chemotherapy agents caused some cells to die, but others resisted.  The remaining cells showed 
increased concentration of CD44+/CD24-/low cells. [124]   
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CD44+/CD24-/low cells have also demonstrated high tumorigenicity, where only 100-200 cells 
were required for tumor growth, whereas, tens of thousands of other phenotypes failed to form a 
tumor.[124, 126]  CD44+/CD24-/low cells have also been shown to be strongly correlated to the triple 
negative (TN) diagnosis of breast cancer, where TN demonstrates a high level of expression of 
CD44+/CD24-/low cells.  Specific antibodies tagged with fluorescent probes can be used to identify cells 
expressing CD44 and not expressing CD24. 
4.3.1.2. ALDH 
 
Aldehyde dehydrogenase (ALDH) is a superfamily of enzymes which consists of 19 isoforms.[128]   
ALDH is an intracellular detoxifying enzyme which is known to metabolize aldehydes to carboxylic acids 
through an oxidation reaction. [128, 129]  These enzymes are also known to play a role in the oxidation 
of retinal to retinoic acid, [128, 130] as well as in the metabolism of some chemotherapy agents, such as 
cyclophosphamide.[128, 131, 132]   
The isolation of ALDH+ cells is possible using a kit called ALDEFLUOR which is manufactured by 
Stemcell Technologies.[124]  Using the kit, ADLH+ cells are able to be identified and sorted by 
Fluorescence Activated Cell Sorting (FACS). 
Using the ALDEFLUOR kit, some clinical studies have shown that an elevated expression of ALDH 
activity had been linked to poor clinical outcomes, and that ALDH+ cells are capable of self-renewal in 
vitro. [15]   Studies have also been performed to determine the tumorigenicty of ALDH+ cells.  It was 
observed that NOD/SCID mice injected with as few as 500 ALDH+ cells developed a tumor. [133]  
Combination of ALDH and the cell surface markers (CD44+/CD24-) further amplified the tumorigenicity 
where only 20 cells were required for tumor growth. [133] 
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4.3.2. Resistance of Cancer Stem Cells 
 
CSC are believed to show similar properties to normal stem cells including relative order, 
resistance to drugs and toxins, active DNA repair capacity and resistance to apoptosis.  Therefore, CSCs 
are pluripotent, chemotherapy resistant cells that are capable of reinitiating tumor growth.[124]   
CSCs have also been shown to be resistant to radiotherapy.  The resistance is believed to be due 
to DNA damage checkpoints and an increase in the DNA repair cycle, through cell cycle-regulating 
proteins CHEK1 and CHEK2.  This same resistance was observed in the breast cancer cell line, MCF-7, 
where following radiotherapy an increase in the CSC population (CD44+/CD24-/low) was observed.[124]  
4.3.2.1. Membrane Efflux Transporters 
 
The overexpression of membrane efflux transporters, namely the ABC transporter family (ATP-
binding cassette transporters), have been identified as a potential source of CSC resistance.  The three 
genes that have been most studied have been ABCB1, ABCG2 and ABCC1, which encode the proteins, P-
glycoprotein, Breast Cancer Resistance Protein, and MRP1, respectively.[124] 
Breast cancer resistance protein (BCRP) or ABCG2 appeared to be upregulated in breast cancer 
stem cells isolated from breast cancer cell lines MCF-7 and MDA-MB-231 cells by 5.8 and 3.6 fold.[115, 
134]  The selection of cells that overexpress BCRP through the dye exclusion assay are referred to as the 
side population (rather than a CSC population).[124]  Therefore, the elevated expression of BCRP in 
breast cancer stem cells could decrease the intracellular concentrations of certain anti-cancer agents, 
which could lead to the resistance of anti-cancer agents by CSCs. 
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5. CONCLUSIONS 
Breast cancer cell lines and breast cancer tumors have been classified into various subtypes 
using two different classification systems.  For breast cancer cell lines, three subtypes are used, Luminal, 
Basal A and Basal B, whereas breast cancer tumors are grouped into five subtypes, Luminal A, Luminal B, 
Basal-Like, HER2 overexpressing and normal-like.  Generally, luminal subtypes contain membrane and 
intracellular receptors, such as estrogen receptors, progesterone receptors, and the human epidermal 
growth factor receptor 2 (HER2), and therefore can be treated with effective targeted treatments 
against these receptors.  Basal subtypes are often associated with the triple negative cancer because 
they do not contain breast cancer receptors, and therefore cannot be treated with targeted treatments. 
A resistance to anti-cancer agents used in the treatment of breast cancer is often observed, and 
this leads to a treatment failure for breast cancer patients.  Some research shows that this resistance is 
due to the presence of breast cancer stem cells, as well as the presence of enzymes involved in the 
bioavailability of medications.  Membrane transporters have been shown to be overexpressed in cells 
resistant to anti-cancer agent as well as in breast cancer stem cells.   
However, our focus has been on the effects of the phase I metabolizing enzymes, Cytochrome 
P450s on the bioavailability of anti-cancer agents because many of these agents are metabolized by 
CYP450s.  Some anti-cancer agents used in the treatment of breast cancer that are metabolized by 
CYP450s include tamoxifen, paclitaxel and cyclophosphamide.  
CYP450s are involved in the systemic metabolism and local metabolism of xenobiotics as well as 
in the metabolism of endogenous molecules (such as steroids).  The overexpression of some CYP450s, 
such as CYP1B1, has been associated with the development of breast cancer.  CYP1B1 is particularly 
associated with breast cancer because many of its substrates, such as benzanthracene, benzo(a)pyrine, 
DMBA, 1-ethynyl-pyrene, 3-methyl-cholantrene and oestradiol, form metabolites which are considered 
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carcinogenic.[97]  CYP1B1 and 2J2 are two isoforms which are of particular interest in breast cancer 
because they demonstrate an elevated expression in breast cancer cell lines.  CYP1B1 is mainly 
implicated in the metabolism of endogenous molecules such as estrogens, while CYP2J2 plays a role in 
fatty acid metabolism.  However, high active site homology is present between CYP1A1/2 and 1B1 as 
well as between CYP3A4 and 2J2 which suggests that many xenobiotics which are metabolized by 
CYP1A1/2 and 3A4 could also be substrates of CYP1B1 and 2J2, respectively.   
While there is a lack of metabolism studies of anti-cancer agents by CYP1B1 and 2J2, it has been 
shown that these two enzymes are implicated in the metabolism of the anti-cancer agent tamoxifen.  
Therefore, other anti-cancer agents may also be metabolized by these two enzymes.  Therefore the local 
metabolism potential of CYP1B1 and 2J2 are of interest as a potential source of resistance to anti-cancer 
agents.   
Many SNPs have been documented for CYP1B1 and 2J2, some of which result in a loss of 
function.  Therefore, the presence of these mutations may result in a decrease in enzyme efficiency and 
affect the intracellular concentrations of some anti-cancer agents. 
 In conclusion, CYP450s may play a crucial role in the local metabolism of anti-cancer agents, 
which may explain the resistance that is observed in patients.  This may also help explain why there is 
such a larger inter-subject variability present between patients. 
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HYPOTHESIS 
Knowing that many chemotherapy agents are substrates of various isoenzymes from the 
superfamily Cytochrome P450 (CYP450), these enzymes may play an important role in the bioavailability 
of many chemotherapy and anti-cancer treatments.  The work executed was to determine if local 
metabolism, at the level of breast tissue, could have a significant impact on the local concentrations of 
chemotherapy agents, and hence be a source of anti-cancer treatment resistance observed in many 
patients. 
 
 
OBJECTIVES OF STUDY 
 This project consisted of several objectives.  However, the majority of the work consisted of 
Real-Time PCR experiments for the determination of mRNA expression of Cytochrome P450s.  In order 
to complete reliable and concrete results, Housekeeping Genes are used to correct of concentration 
errors and product degradation.  Therefore, the first objective was to screen the expression level of six 
potential Housekeeping Genes (β-Actin, GAPDH, NUP-214, PPIG, RPLPO and TBP) in the twenty-three 
cell lines used in house to determine which Housekeeping Gene demonstrated the most stable 
expression.  Most of the screened housekeeping genes were chosen based on their common use in 
RT-PCR studies (β-Actin, GAPDH, RPLPO and TBP), whereas NUP-214 and PPIG, were selected because of 
their stability in paraffin-embedded breast samples. 
 Our secondary objective was to identify and characterize the role of Cytochrome P450s in breast 
cancer.  Using NUP-214 as the most stable Housekeeping Gene, the mRNA expression levels of nineteen 
specific CYP450 isoenzymes were determined by Real-Time PCR. 
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The third objective was to determine if the mRNA expression of the CYP450 isoforms 2J2 and 
1B1 were sufficient to observe the metabolism of ebastine and 7-ethoxyresorufin, specific substrates of 
CYP2J2 and 1B1, respectively.  Finally, correlation studies were completed to determine if mRNA 
expression was capable of predicting metabolic activities in these cell lines. 
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ABSTRACT 
Background: The accuracy of quantitative Real-Time PCR is highly dependent on a stable and reliable 
housekeeping gene.  Certain endogenous genes, such as glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) and β-Actin are commonly used to correct for mRNA degradation and concentration 
differences.  However, these genes have been shown to be affected by experimental conditions and 
therefore cannot serve as ubiquitous controls.  The need to identify a more stable control housekeeping 
gene is therefore required. 
Results: The expression levels of six potential control genes (β-Actin, GAPDH, NUP-214, PPIG, RPLPO, 
TBP) were tested in a variety of cancer and non-cancer cell lines (n=23) (including breast cancer (n=7), 
endometrial cancer (n=5) and ovarian cancer (n=4)) in order to determine which gene could serve as a 
stable housekeeping gene.  The results showed that NUP-214 was the most stable control gene for all 
samples analyzed with a standard deviation of 0.55 Ct (CV=2.5%).  β-Actin and GAPDH, showed greater 
variabilities, with standard deviations of 0.96Ct (CV=5.4%) and 1.01 Ct (CV=5.7%), respectively.  PPIG 
which demonstrates a standard deviation of 1.243Ct (CV=4.3%) was not expressed in muscle cells. 
Conclusions: Therefore, PPIG, β-Actin and GAPDH may be useful housekeeping genes under selected 
conditions.  However, we propose that NUP-214 can be used with less restriction as a housekeeping 
gene for RT-PCR analyses for cultured cells. 
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BACKGROUND 
The correction or normalization of mRNA expression data by Real-Time Polymerase Chain 
Reaction (RT-PCR) is required to determine if relevant expression differences are present between 
samples.  Commonly, normalization is performed using an endogenous gene, such as a housekeeping 
gene (HKG).   Housekeeping genes are genes which are constitutively expressed because they are 
required for basic cell maintenance, and therefore should show stable expression despite treatments, 
stresses or experimental conditions.[1]  However, many reports have shown that commonly used HKGs 
are not appropriate for all experimental conditions and therefore cannot be used to correct for RNA 
integrity.[2] 
Most commonly used reference genes include: GAPDH, β-Actin, TATA-box binding protein (TBP) 
and Large Ribosomal Protein (RPLPO) (See Table 1 for gene details).  Each of these genes plays a crucial 
role in the cell maintenance and growth.  Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is 
essential for the production of cellular ATP, β-Actin is a cytoskeletal protein, TBP is a transcription factor 
while the RPLPO is required for Peptide Synthesis. 
Previously Nucleoporin 214 (NUP-214) and Peptidyl-prolyl cis-trans isomerase G (PPIG) were 
demonstrated to be the most stable HKG in breast tumour formalin-fixed, paraffin-embedded 
samples.[3]  NUP-214 (also known as CAN), is a protein localized to the Nuclear Pore Complex (NPC), 
which is responsible for the transport of macromolecules inside and out of the nucleus.[4]  PPIG is an 
enzyme which is responsible for the cis/trans isomerase reactions of amino acid side chains during the 
protein folding process.[5]  Both these genes encode for proteins which play a crucial roles in the 
maintenance and growth of cells, which suggests mRNA stability of these genes.[3]  
Therefore, the goal of this study is to evaluate the expression levels of six different HKGs in a 
variety of cell lines (coming from different pathologies and tissues), to determine which gene shows the 
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most stable expression pattern.  If a stable HKG is present across the various cell lines, it could be 
utilized to correct for concentration differences and RNA integrity. 
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MATERIALS AND METHODS 
Materials.   
RPMI, DMEM, DMEM/F12 medias, Trypsin/EDTA and Fetal Bovine Serum (FBS) were purchased from 
Wisent Inc (St-Bruno, QC, Canada).  MEGM bulletkit and SkGM bulletkit were purchased from Lonza 
(Walkersville, MD, USA).  The following cell lines from various cancer sources were purchased from the 
ATCC (Manassa, VA, USA): Breast cancer (Hs578T, MCF-7, MDA-MB-231, MDA-MB-468, SKBR3, T47D, 
and ZR-75-1), Ovarian and endometrial cancer (AN3 CA, CaOV-3, ES-2, Hec-1B, KLE, NIH:OVCAR-3, PA-1, 
RL-95-2, and SKOV-3),  Cervix Cancer (Hela), Hepatocellular Cancer (HepG2), and Colorectal Cancer 
(Caco2).  Three  benign cell lines served as controls, i.e. SkMC (Human skeletal muscle cells) purchased 
from Lonza, while Hek293T (embryonic kidney cell line), and MCF-10A (breast tissue cell line) were 
purchased from the ATCC.  RNA extractions were performed using the QIAGEN RNA extraction Kit 
(Quiagen Sciences, MD, USA).  SuperScript II Reverse Transcriptase, random primers and RNaseOUT 
Recombinant Ribonuclease Inhibitor were purchased from Invitrogen (Carlsband, CA, USA).  25mM dNTP 
mix was purchased from Wisent (St-Bruno, QC, Canada).  Taqman Universal PCR Mix, probes and HKG 
were purchased from Applied Biosystems (Foster, CA, USA). 
 
Cell Culture.   
Caco2, CaOV-3, HELA, HepG2, Hs578T, MCF-7, MDA-MB-231, MDA-MB-468 and SKBR3 were cultured in 
DMEM media supplemented with 10% fetal bovine serum (FBS).  NIH:OVCAR-3, T47D, and ZR-75-1 were 
cultured in RPMI supplemented with 10% FBS. AN3-CA, Hec-1-B, Hek293T and PA-1, were cultured in 
EMEM supplemented with 10% FBS, 5mL NEAA and 5 mL L-Glutamine.  ES-2 and SKOV-3 were cultured 
in McCoy’s 5A media supplemented with 10% FBS.  MCF-10A was grown in MEGM media (Lonza) while 
KLE was grown in DMEM/F12 supplemented with 10% FBS and RL-95-2 in DMEM/F12 supplemented 
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with 10% FBS and 0.005ng/mL insulin.  SkMC cells were grown in SkGM media (Lonza), while SkMC 
statin-induced cells were induced for 6 days with 2 μM Simvastatin.  All cells were cultured at 37°C with 
5% CO2.   
 
RNA Extraction.   
Cell lines were grown to 70% confluency before RNA isolation.  Briefly, cells were washed with PBS, 
trypsinized, and harvested at 100 x g.  Under RNase free conditions, and using the QIAGEN RNA 
extraction kit, RNA was harvested and quantified by UV absorption at 260 and 280nm.  RNA was stored 
at -80°C until use. 
 
Reverse Transcriptase.   
Isolated RNA was used to synthesize cDNA, where each 20 µL mixture contained 1 µg of RNA, 40 units of 
RNaseOUT inhibitor, 200 units of Superscript II reverse transcriptase, 3 µg of random primers, 1.25 mM 
dNTP, 10 mM DTT in first-strand buffer (at a final concentration of 50 mM Tris-HCl, pH 8.3; 75 mM KCl; 3 
mM MgCl2).  Reverse transcriptase cycle was performed as per manufacturer’s protocol.  Briefly, RNA, 
random primers and water was heated at 65°C for 5 minutes.  Contents were placed on ice.  A second 
mixture containing buffer, DTT, RNaseOUT and Superscript was added to the RNA mix, which was then 
placed back in the thermal cycler (2720 Thermal Cycler, Applied Biosystems) and heated at 42°C for 50 
minutes.  Mixture was then inactivated by heating at 70°C for 15 minutes.  cDNA was then aliquoted and 
stored at -80°C. 
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Real-Time-PCR Standard Curves.   
All RT-PCR runs were performed using the RotorGene RG6000 (Corbett Research, Mortlake, Australia).  
Standard curves were prepared for each HKG using the RNA isolated from various cell lines known to 
highly express the RNA of interest.  Samples contained 1 µL of 20X probes, 10 µL of 2X TaqMan Universal 
Mix and 4 µL of cDNA (final concentration ranging from 40-0.156 ng), where the final assay volume was 
completed to 20 µL with water.  All samples were prepared on ice.  Thermal cycling conditions were as 
follows: 95°C for 10 minutes, followed by 45 cycles of 95°C for 10 seconds and 60°C for 45 seconds.  
Every standard curve was validated using the technique described by Livak et al. in 2001, using Ct/log of 
cDNA concentration curve. [6] 
 
Housekeeping Gene Selection.   
Six commonly used HKG (GAPDH, NUP-214, PPIG, β-Actin, RPLPO and TBP) were tested in the twenty-
three cell lines to determine which HKG would be the most stable. Samples were prepared in triplicate 
and contained 1 µL of 20X probes, 10 µL of 2X TaqMan Universal Mix and 4 µL of cDNA (final 
concentration of 10 ng), where the final assay volume was completed to 20 µL with water.  The thermal 
cycling was as described for Standard Curves.  Cycle thresholds (Ct) were determined and the deviation 
from average was determined. 
 
Housekeeping Gene Relative Expression.   
The stability of the six HKGs (GAPDH, NUP-214, PPIG, β-Actin, RPLPO and TBP) was assessed by 
calculating the relative expressions for each gene.  Comparative relative expression levels were 
determined using the following equation: 
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Relative Expression: 2-(Ct HKG-Ct HKG Average) 
 
Housekeeping Gene Stability Analysis. 
 The stability of the six HKGs (GAPDH, NUP-214, PPIG, β-Actin, RPLPO and TBP) was assessed using an 
online database (Cotton EST Database). [7] This database gives a comprehensive assessment of the 
reference genes stability using four different methods; Delta CT, BestKeeper, Normfinder and Genorm. 
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RESULTS 
Six commonly used HKG were tested in twenty-three cell lines to determine which gene would 
be the most stable and therefore better able to correct for RNA integrity.  Threshold cycles (Ct) were 
determined for the six HKG, and the averages and standard deviations were calculated (Table 2).  The 
stability or deviation of the cell lines HKG expression was analyzed to determine which HKG showed the 
smallest variations between samples (Figure 2).  The online database Cotton EST was also used to 
determine the stability of these reference genes (Table 3). 
The expression of each HKG, from most expressed to least expressed is as follows, where the 
values in Ct are shown: RPLPO (14.624), GAPDH (17.792), β-Actin (17.824), NUP-214 (21.750), TBP 
(22.356) and PPIG (28.723).  The expression level of the HKG is an important aspect to consider when 
choosing a candidate gene.  When the expression of a gene is very strongly expressed, slight 
degradation of the product is going to be less significant than a gene that is more weakly expressed.  
However, a gene that is weakly expressed will generate more variability in RT-PCR analyses, and 
therefore yield less reliable results.  Thus, a gene which is moderately expressed (around 20 Cts) like 
NUP-214 will be sensitive enough to RNA degradation, but will be very stably expressed.   
In order to evaluate the stability of each gene, the standard deviations for the inter-cell line 
expression and percent CVs were calculated, and is as follows: RPLPO (0.587Ct, 4.0%), GAPDH (1.014Ct, 
5.7%), β-Actin (0.961Ct, 5.4%), NUP-214 (0.546Ct, 2.5%), TBP (0.715Ct, 3.2%) and PPIG (1.243, 4.3%), 
respectively (see Table 2).  Therefore, based on standard deviations, the order of stability for these 
genes are the following: NUP-214, RPLPO, TBP, β-Actin, GAPDH, and finally PPIG.  However, based on 
percent CV, the stability order would be: NUP-214, TBP, RPLPO, PPIG, β-Actin, and GAPDH.  In either 
case, it can be seen that NUP-214 is the most stable.  
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Relative expressions can be calculated to evaluate the inter-cell line variability, and therefore 
gene stability.  Figure 1 shows the relative expressions of each gene in each cell line.  When a value is 
around 1, it signifies that the gene demonstrates around average expression.  When a value is greatly 
above 1, the gene is more greatly expressed in that cell line compared to the other cell lines.  Therefore, 
genes which demonstrate the least amount of deviation from 1 (or average) can be said to be more 
stable.  As it can be seen, both NUP-214 and RPLPO demonstrate relative expressions that are less that 
2, but greater than 0.5 Cts.  Since two cell lines did not express the gene PPIG, this gene shows large 
variations in relative expression, and should not be used as a reference gene. 
Another way to evaluate the stability of these genes is to look at how much variability in gene 
expression is present between cell lines.  Figure 2 shows the frequency distribution of variability for each 
gene, where the average expression (in Ct), was set at 0.  Therefore, if a cell line has a much greater or 
weaker expression of a particular gene, there would be a greater difference from the average.  The 
largest ∆Ct that is present for each gene is as follows: β-Actin (1.5), GAPDH (2.0), NUP-214 (1.0), PPIG 
(4.0), RPLPO (1.0) and TBP (1.5).  This data demonstrates the same order of stability for each gene as 
when looking simply at the standard deviation. 
Finally, the online database Cotton EST was used to determine the stability of each reference 
gene.  This database uses four methods (Delta CT, BestKeeper, Normfinder and Genorm) in order to 
determine which reference gene is the best. Table 3 lists the rankings of each method, along with a 
comprehensive ranking.  The data shows that NUP-214 is the most stable reference gene using each 
system, whereas PPIG is the worst. 
Therefore, NUP-214 has the smallest overall standard deviation, of 0.55 Ct, demonstrates a ∆Ct 
of 1.0, and was evaluated as the best HKG by the Cotton EST database.  Overall, all analyses lead to the 
same conclusion; NUP-214 is the most stable HKG candidate.    
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DISCUSSION 
Results in this study demonstrate that NUP-214 is the most stable of the HKGs  analyzed in the 
twenty-three cell lines tested, despite their tissue source or pathology.  Among the results, PPIG, GAPDH 
and β-Actin were the least stable or variably expressed genes in these same cell lines.  Therefore, 
NUP-214 is the superior choice as a HKG and can be used to effectively analyze mRNA differences 
between samples. 
Housekeeping genes are genes which are constitutively expressed due to a cellular need for 
these specific proteins.  In RT-PCR, HKGs are used to correct for RNA integrity as well as small 
concentrations differences which may exist from one sample to another.  However, in some cases, 
classic HKG genes cannot be used when experimental conditions cause large variations in the gene’s 
expression.  Therefore, the selection of a stable HKG is important to ensure that the RNA is of good 
quality.  The goal of this study was to determine if there was a HKG (among GAPDH, β-Actin, RPLPO, TBP, 
NUP-214 and PPIG) that is stable across many different types of cells and which contain a variety of 
pathologies. 
While NUP-214 and PPIG are not commonly evaluated or used as HKGs, these two genes had 
been previously shown to be stably expressed in formalin-fixed paraffin-embedded (FFPE) breast cancer 
tissue [3].  Since NUP-214 and PPIG were so stable in FFPE breast cancer tissue, the stability of these two 
genes in breast cancer cell lines were of interest.  NUP-214 proved to be the most stable HKG candidate 
for the 7 breast cancer cell lines analysed (and 1 non-cancerous breast cell line).   Since NUP-214 is 
almost never evaluated as a HKG candidate (except for in the paper by Iverson AA in 2009), we wanted 
to determine if NUP-214 was universally stable in cell lines isolated from various tissues and pathologies, 
or if its expression stability was purely related to breast cancer cells.  As can be seen in Figure 1 and 2, 
NUP--214 is truly the most stable HKG candidate among the various cell lines evaluated. 
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The second most stable HKG determined was RPLPO with a standard deviation of 0.59 Ct.  While 
this gene is a much better choice compared to GAPDH or β-Actin, it’s stability is less than NUP-214.  One 
issue that can be foreseen for RPLPO is the fact that it’s expression level is much stronger than that of 
NUP-214 (with an average Ct of 14.62 compared to 21.75 for NUP-214).  Currently these results are 
based on RNA that was freshely isolated from cell lines that are grown under ideal conditions.  
Therefore, little to no degradation is present in the RNA.  Since degradation is less apparent for genes 
which are very strongly expressed, small degradation of RNA samples may not be accurately corrected 
for when using RPLPO due to its strong expression. 
Overall, NUP-214 proves to be an excellent option as a HKG candidate.  Not only is the gene 
stabilily expressed between cell lines, but is also stable within the cell line (ie, the Ct has very low 
variation, and so has a small standard deviation).  NUP-214 is also an excellent choice because of it’s 
expression level (average Ct of 21.75).  Therefore, its expression is weak enough that it will correct for 
RNA integrity, but strong enough that it  shows very little variations between repeats.  Therefore, based 
on this data, NUP-214 could serve as a universal HKG candidate for a variety of cell lines.   
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CONCLUSION 
In conclusion,  we performed a thorough evaluation of the stability of six candidate HKGs 
(β-Actin, GAPDH, NUP-214, PPIG, RPLPO, TBP) in twenty-three different cell lines (coming from different 
pathologies and isolated from different tissues).  This study serves to determine which candidate HKG is 
the most stablily expressed to determine if a universal HKG can be idenified.  Overall, the results 
demonstrate that NUP-214 is the most stable HKG identified in the different cell lines tested, and could 
serve as a universal HKG. 
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Table 1: Panel of 6 candidate housekeeping genes 
General information for each of the candidate housekeeping genes evaluated. 
 
Gene Symol mRNA Accession 
Number 
Gene Name Function Gene Aliases 
NUP-214 
(Hs01090093_m1*) 
NM_005085 Nucleoporin 
214kDa 
Nuclear Pore 
Complex 
CAIN 
CAN 
D9S46E 
MGC104525 
N214 
RP11- 
544A12.7 
PPIG 
(Hs01081188_gH*) 
NM_004792 Peptidylprolyl 
isomerase G 
(cyclophilin G) 
Cis/Trans 
Isomerization 
enzyme 
CARS-Cyp 
CYP 
MGC133241 
SCAF10 
SRCyp 
ACTB NM_001101 Beta-Actin 
(β-Actin) 
Cytoskeletal 
structural protein 
 
GAPDH NM_002046 Glyceraldehyde-3-
phospate 
dehydrogenase 
Glycolytic enzyme G3PD 
GAPD 
RPLPO NM_001002 Large Ribosomal 
Protein 
Peptide Synthesis L10E 
MGC111226 
MGC88175 
P0 
PRLP0 
RPP0 
TBP NM_003194 TATA-box binding 
protein 
Transcription 
factor 
GTF2D 
GTF2D1 
HDL4 
MGC117320 
MGC126054 
MGC126055 
RP1-191N21.3 
SCA17 
TFIID 
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Table 2: Expression of housekeeping genes 
The expression of each housekeeping gene in all cell lines is listed in Threshold Ct.  The data was 
performed in triplicate and the table lists the standard deviation of the gene for each cell line.  The 
average Ct, overall standard deviation and percent CV was calculated for each gene using all cell lines.  
(ND: Not detected). 
 
Gene β-Actin GAPDH NUP-214 PPGI RPLPO TBP 
KLE 16.15 ± 0.06 17.68 ± 0.38 22.00 ± 0.59 28.35 ±0.08 15.18 ± 0.32 22.50 ± 0.91 
RL-95-S 17.21 ± 0.07 18.57 ± 0.36 21.56 ± 0.09 27.83 ± 0.23 15.09 ± 0.05 23.63 ± 1.23 
SK-OV-3 17.65 ± 0.17 18.05 ± 0.04 21.58 ± 0.08 27.82 ± 0.09 15.29 ± 0.21 21.29 ± 0.60 
CA-OV-3 16.28 ± 0.24 15.54 ±0.06 21.46 ± 0.21 28.78 ± 0.32 13.82 ± 0.18 21.74 ± 0.15 
ES-2 19.42 ± 0.29 18.19 ± 0.05 22.04 ± 0.09 28.88 ± 0.31 14.55 ± 0.20 23.65 ± 0.30 
PA-1 16.31 ± 0.04 17.9 ± 0.02 21.01 ± 0.10 32.67 ± 0.29 14.2 ± 0.07 21.71 ± 0.09 
Hec-1B 17.88 ± 0.04 18.2 ± 0.01 22.26 ± 0.07 29.65 ± 0.23 15.09 ± 0.09 22.53 ± 0.66 
OVCAR-3 17.38 ± 0.03 17.31 ± 0.06 20.82 ± 0.06 28.28 ± 0.12 14.84 ± 0.26 21.57 ± 0.17 
AN3 CA 18.42 ± 0.03 18.52 ± 0.40 22.18 ± 0.09 30.27 ± 0.18 15.48 ± 0.10 22.28 ± 0.25 
HS578T 17.26 ± 0.04 17.17 ± 0.18 21.7 ± 0.28 28.76 ± 0.17 14.53 ± 0.22 22.04 ± 0.16 
SKBR3 18.31 ± 0.02 17.7 ± 0.13 21.3 ± 0.19 27.44 ± 0.12 14.00 ± 0.17 20.81 ± 0.25 
MDA-MB-468 17.78 ± 0.13 16.81 ± 0.04 21.94 ± 0.22 28.72 ± 0.16 14.99 ± 0.01 22.54 ± 0.18 
MDA-MB-231 17.74 ± 0.13 16.97 ± 0.12 21.78 ± 0.10 29.57 ± 0.26 14.09 ± 0.07 23.17 ± 0.60 
MCF-7 19.24 ± 0.17 18.36 ± 0.03 22.83 ± 0.12 28.46 ± 0.28 13.39 ± 0.01 22.49 ± 0.17 
MCF-10A 14.68 ± 0.01 16.54 ± 0.23 21.8 ± 0.14 28.18 ± 0.14 15.15 ± 0.24 22.28 ± 0.26 
T47D 18.19 ± 0.07 18.83 ± 0.03 21.1 ± 0.06 27.47 ± 0.29 14.44 ± 0.11 23.11 ± 0.01 
ZR-75-1 17.17 ± 0.02 15.66 ± 0.05 21.6 ± 0.05 26.48 ± 0.13 14.54 ± 0.10 22.41 ± 0.14 
HeG2 18.99 ± 0.02 19.48 ± 0.05 21.73 ± 0.06 28.42 ± 0.13 14.92 ± 0.10 22.43 ± 0.03 
Caco2 17.84 ± 0.18 17.41 ± 0.09 21.65 ± 0.06 28.27 ± 0.11 14.98 ± 0.12 21.69 ± 0.24 
Hela 17.68 ± 0.41 17.49 ± 0.16 21.55 ± 0.22 29.01 ± 1.21 15.29 ± 0.5 22.14 ± 0.55 
Hek293 17.02 ± 0.23 17.65 ± 0.15 20.93 ± 0.37 29.53 ± 1.9 15.49 ± 0.73 21.88 ± 1.2 
SkMC 19.34 ± 0.14 19.37 ± 0.01 22.8 ± 0.08 ND 14.13 ± 0.41 23.06 ± 0.28 
SkMC Statin Induced 19.16 ± 0.17 19.15 ± 0.06 22.6 ± 0.12 ND 14.09 ± 0.47 22.88 ± 0.25 
Average 17.824 17.792 21.75 28.723 14.624 22.356 
Standard Deviation 0.961 1.014 0.546 1.243 0.587 0.715 
Percent CV 5.40% 5.70% 2.50% 4.30% 4.00% 3.20% 
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Table 3: Cotton EST database evaluation of reference gene expression 
Data imported into online database, were reference gene expression was evaluated using four different 
methods (Delta CT, BestKeeper, Normfinder, and Genorm).  For the cell line that did not express PPIG a 
value of 40 was used for calculation purposes. 
 
Method 
Ranking (best to worst) 
1 2 3 4 5 6 
Delta CT NUP-214 TBP β-Actin GAPDH RPLPO PPIG 
BestKeeper NUP-214 RPLPO TBP β-Actin GAPDH PPIG 
Normfinder NUP-214 GAPDH β-Actin TBP RPLPO PPIG 
Genorm NUP-214/TBP β-Actin GAPDH RPLPO PPIG 
Recommended 
comprehensive 
ranking 
NUP-214 
(1.00) 
TBP 
(2.21) 
β-Actin 
(3.22) 
GAPDH 
(3.56) 
RPLPO 
(3.98) 
PPIG 
(6.00) 
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Figure 1:  Housekeeping gene stability 
Relative expression calculated using the average threshold cycle as the equilibrator for each gene.  All 23 cell lines are shown for each gene.  PPIG was 
not expressed in muscle cells, so the relative expression was calculated using 40 as a Ct value 
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Figure 2: Frequency distributions of housekeeping gene expression 
Average threshold cycle was calculated for each gene, and is placed at 0.  Data shows that 
NUP-214 has the least deviation between the cell lines for the housekeeping genes tested. 
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ABSTRACT 
Background : Cytochrome P450 (CYP450) enzymes are known to be involved in the metabolism of 
chemotherapy agents that are commonly used in the treatment of breast cancer.  While CYP450s 
are primarily found in the intestines and liver, where they likely control the systemic exposure to 
drugs, they are also present at significant levels in other tissues.  In such tissues, they would be 
responsible for the local metabolism of drugs.  Hence, variable expression of CYP450 genes at the 
tissue level, next to their effector site, could explain inter-subject variability in the local 
metabolism, efficacy and toxicity of drugs.  In order to determine if gene expression is variable for 
these enzymes, their expression level of mRNAs in breast cancer cell lines and functional CYP450 
activities were evaluated.  Methods: Seven commonly used breast cancer cell lines, (Hs578T, 
MDA-MB-231, MDA-MB-468, MCF-7, SKBR3, T47D, ZR-75-1) and one benign breast cell line (MCF-
10A) were cultured and then extracted for RNA.  The RNA was reverse transcribed to cDNA where 
the mRNA levels of 19 CYP450 isoenzymes were determined by Quantitative Real-Time PCR.  
Functional activities of CYP1B1 and 2J2 were determined by incubating whole cells with 
7-ethoxyresorufin and ebastine, respectively, and measuring the metabolite produced by LC-MS. 
Results:  The relative mRNA levels of the different CYP450 enzymes showed a large variability 
between the different cell lines.  CYP1B1 mRNA was highly expressed in most of the breast cancer 
cell lines; CYP2J2 mRNA is the most abundant CYP450 found in SKBR3 and ZR-75-1 cell lines 
contributing 62.9 and 15.4%  of  their total CYP450 make-up respectively; CYP3A4/5/7 mRNAs 
expressions were 41.5, 13.9 and 43.3 times greater in the benign control compared to the mean 
value; whereas 2C9 mRNAs showed no expression in any cell line analyzed.  The metabolism of 
7-ethoxyresorufin was observed in 4 of the 8 cell lines, where the Km observed was between 0.05 
to 0.1 µM and Vmax ranged from 0.04 to 3.7 pmol/mg protein/min.  The metabolism of ebastine 
was observed in 7 of the 8 cell lines, where the Km was between 0.2 and 3.1 µM and Vmax 
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between 0.58 and 2.6 pmol/mg protein/min. Correlation studies between mRNA expression of 
CYP1B1 and CYP2J2 and the metabolism of 7-ethoxyresorufin and ebastine, respectively, revealed 
very strong correlations of 0.98 and 0.99, respectively. Conclusion: The variability in expression 
levels of CYP450 mRNAs appears to be characteristic of the different cell lines analyzed.  We 
propose that the variable expression of CYP450s in breast cancer cells could explain part of the 
inter-subject variability in response to chemotherapy agents.  The variability of CYP450 mRNAs 
expression may also identify new targets for the synthesis of anti-cancer agents. 
Keywords: Breast Cancer, mRNA, qualitative RT-PCR, CYP1B1, CYP2J2  
 75 
 
INTRODUCTION 
The cytochrome P450 (CYP450) superfamily is a family of enzymes which work to detoxify the 
body of many xenobiotic molecules by biotransforming them into more hydrosoluble 
molecules.[1]  In human, there are 57 known CYP450 isoforms which have been classified based 
on their sequence homology, and have various roles in the metabolism and synthesis of 
molecules.  CYP450s isoforms play an important role in the synthesis and degradation of many 
endogeneous molecules, such as steroids.  CYP1A1, 1A2 and 1B1 have been shown to be 
implicated in the hydroxylation of progesterone, testosterone and estrogen. [2-5]  CYP17A1 and 
19A1 are two isoforms which are also important in the formation of androstenedione through the 
use of aromatase activity. [3,6]  Since these steroids have been shown to impact breast cancer 
survival and treatment, these isoforms will be important to evaluate. [7] 
 
CYP450s are most abundantly found in the liver, where CYP3A4 is considered the most important 
for drug metabolism.  However, the presence of CYP450 enzymes, with tissue specific expression, 
have been shown in other tissues such as the intestines, kidneys, brain, lungs and heart at varying 
concentrations. [8-15]  The expression of specific enzymes in extra hepatic tissue shows that local 
metabolism could play an important role in drug metabolism and cause a source of variation in 
drug effects. 
 
Many chemotherapy agents, both active drug and pro-drug, are known substrates of CYP450s.[16]  
Therefore, the presence of CYP450s at both the intestinal/hepatic level and the tissular level will 
influence the response of chemotherapy agents.  At the hepatic level, the CYP450s present cause 
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decreased bioavailability of medications.  The portion of the medication that reaches the targeted 
cells would then encounter other CYP450s which would locally metabolize the drug (either for 
clearance or activation purposes). For active drugs, if the molecule is a substrate of a specific 
CYP450 highly expressed in the cells of interest, it would be metabolized too quickly from the 
targeted cell and cause no local effect; whereas a pro-drug which requires CYP450 metabolism 
could be activated locally due to the presence of a specific enzyme at the targeted site.  Since 
tissue specific expression of CYP450 enzymes are expected so is the metabolism potential.  
 
Inter-subject variability of CYP450 mRNA expression would be expected in breast tissue based on 
similar results observed in other tissues.  This can also be suggested when evaluating the efficacy 
of chemotherapy agents in breast cancer cell lines.  A study performed in 2009 evaluated the 
effects of three chemotherapy agents in nineteen breast cancer cell lines to determine the efficacy 
of the chemotherapy agents.  The study showed that not every chemotherapy agent was effective 
in all cell lines analyzed which shows that inter-subject response is present.[17]  Since 
chemotherapy agents are substrates of CYP450 enzymes, the response difference of the cell lines 
may be partly explained by the presence of differing CYP450 expression. 
  
Therefore, we believe that breast tumors will display variations in CYP450 expression, and this 
tissue specific expression could cause a variation in local metabolism which is an important 
phenomenon to consider in breast cancer treatment and survival.  To evaluate this point, 
commonly used cell lines were analyzed for mRNA expression of CYP450 enzymes, which we 
believe will display inter-cell line variation, which would indicate a potential variation in breast 
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cancer patients.  In addition, functional activities of CY1B1 and 2J2, two isoforms which have been 
shown to be highly expressed through this work, were determined using two specific substrates, 
7-ethoxyresorufin and ebastine, respectively.  These differences could help identify new pathways 
for the synthesis of new anti-cancer agents, either as pro-drug or active drugs. 
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MATERIALS AND METHODS 
Materials.  RPMI, and DMEM medias, trypsin/EDTA and fetal bovine serum (FBS) were 
purchased from Wisent Inc (St-Bruno, QC, Canada).  MCF-7, SKBR3, Hs578T, MDA-MB-231, 
MDA-MB-468, T47D, ZR-75-1 and MCF-10A were purchased from the American Type 
Culture Collection, ATCC (Manassa, VA, USA).  RNA extractions were performed using the 
QIAGEN RNA extraction kit (Quiagen Sciences, MD, USA).  Superscript II reverse 
transcriptase, random primers and RNaseOUT recombinant ribonuclease inhibitor were 
purchased from Invitrogen (Carlsband, CA, USA).  25mM dNTP mix was purchased from 
Wisent (St-Bruno, QC, Canada).  Taqman universal PCR mix, probes and housekeeping 
genes (HKGs) were purchased from Applied Biosystems (Foster, CA, USA).  MEGM media 
with bulletkit and MycoAlert mycoplasma detection kit were purchased from Lonza 
Rockland Inc (Rockland, ME, USA).  Ebastine, hydroxy ebastine, carebastine, 2H5-
hydroxyebastine, 2H5-carebastine and 
2H6-hydroxybupropion and 7-ethoxyresorufin were 
purchased from Toronto Research Chemicals (North York, Ontario, Canada).  Resorufin 
sodium salt, cholera toxin, glucose-6-phoshate, magnesium chloride, β-nicotinamide 
adenine dinucleotide phosphate sodium salt hydrate and glucose-6-phosphate 
dehydrogenase were purchased from Sigma (St-Louis, MO, USA).  Pierce BCA protein assay 
kit was purchased from Thermo Scientific (Rockford, IL, USA).  Recombinant supersomes, 
rCYP1A1, 1B1 and 2J2 were obtained from BS Scientific (Mississauga, ON, Canada).  
Acetonitrile and formic acid were obtained from EMD Chemicals (Gibbstown, NJ, USA). 
Other chemicals, including methanol were purchased from Fisher Scientific (Fair Lawn, NJ, 
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USA). Water was deoinized using a Nanopure Barnstead/Thermolyne system (Dubuque, 
IA, USA). 
Cell Culture.  MCF-7, SKBR3, Hs578T, MDA-MB-231 and MDA-MB-468 were cultured in DMEM 
media supplemented with 10% fetal bovine serum (FBS).  T47D and ZR-75-1 were cultured in RPMI 
supplemented with 10% FBS and MCF-10A were grown in MEGM media with supplements and 
0.05 ng/mL cholera toxin.  All cells were cultured at 37°C with 5% CO2 and were tested negative for 
mycoplama. 
 
RNA Extraction.  Cell lines were grown to 70% confluency before RNA isolation.  Briefly, cells were 
washed with PBS, trypsinized, and harvested at 100 x g.  Under RNase free conditions, and using 
the QIAGEN RNA extraction kit, RNA was harvested and quantified by UV absorption at 260 and 
280nm.  RNA was stored at -80°C until used. 
 
Reverse Transcriptase.  Isolated RNA was used to synthesize cDNA, where each 20 µL mixture 
contained 1 µg of RNA, 40 units of RNaseOUT inhibitor, 200 units of Superscript II reverse 
transcriptase, 3 µg of random primers, 1.25 mM dNTP, 10 mM DTT in first-strand buffer (at a final 
concentration of 50 mM Tris-HCl, pH 8.3; 75 mM KCl; 3 mM MgCl2).  Reverse transcriptase cycle 
was performed as per manufacturer’s protocol.  Briefly, a mix containing RNA, random primers 
and water was heated at 65°C for 5 minutes.  Contents were then placed on ice.  A second mixture 
containing buffer, DTT, RNaseOUT and Superscript was added to the RNA mix, which was then 
placed back in the thermal cycler (2720 Thermal Cycler, Applied Biosystems) and heated at 42°C 
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for 50 minutes.  The mixture was then inactivated by heating at 70°C for 15 minutes.  cDNA was 
then aliquoted and stored at -80°C. 
 
Real-Time-PCR Standard Curves.  All Real-Time PCR runs were performed using the RotorGene 
RG6000 (Corbett Research, Mortlake, Australia).  Standard curves were prepared for each CYP450 
using the RNA isolated from various cell lines known to highly express the RNA of interest.  
Samples contained 1 µL of 20X probes, 10 µL of 2X TaqMan Universal Mix and 4 µL of cDNA (final 
concentration ranging from 0.156-40 ng), where the final assay volume was completed to 20 µL 
with water.  All samples were prepared on ice.  Thermal cycling conditions were as follows: 95°C 
for 10 minutes, followed by 45 cycles of 95°C for 10 seconds and 60°C for 45 seconds.  Every 
standard curve was validated using the technique described by previously, using Ct/log of cDNA 
concentration curve. [18] 
 
CYP450 mRNA determination. Expression levels of 19 CYP450 isoenzymes were determined by 
Real-Time PCR.  Samples were prepared in triplicate using the TaqMan universal mix and specific 
CYP450 probes from Applied Biosystems, along with 10 ng of cDNA in a final assay volume of 20 
µL.  The thermal cycling was as described for standard curves.  Cycle thresholds (Ct) were 
determined and the deviation from average was determined.  NUP-214 was used as the 
housekeeping gene (HKG) because it was previously shown to be the most stable.[19]  
Comparative quantitative relative expression levels were determined using the following 
calculations: 
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∆Ct CYP450:   Ct CYP450- CtNUP-214 
∆∆Ct CYP450: ∆CtCYP450- ∆Ct CYP450 median 
Relative Expression: 2-∆∆Ct CYP450 
Total CYP450 mRNA determination. Expression levels of total CYP450 mRNA was determined by 
making a master mix containing all specific probes for the 19 CYP450 isoenzymes.  To a total 
volume of 20 μL, 0.2 μL of each probe was added to 10 μL of 2X Taqman and 10 ng of cDNA.  The 
expression levels were determined using the same conditions as described for the housekeeping 
gene selection.  NUP-214 was used as the HKG.  Comparative quantitative relative expression 
levels were determined using the following above calculations. 
 
Ebastine Metabolism in Breast Cancer Cell Lines.  Cells were plated in 24 well plates and allowed 
to grow to confluence for 3 days.  Cells were then incubated with 500 μL of various concentrations 
of ebastine (0.1 to 5 μM) prepared in DMEM without phenol red or serum.  After 1 hour at 37°C, 
the reaction was stopped by adding 500 μL of 1 M formic acid in acetonitrile.  The reaction mixture 
was collected and centrifuged at 13 rpm for 10 minutes.  100 μL of the supernatant was then 
transferred to a borosilicate tube, where 100 μL of internal standard (25 μg/mL 2H5-
hydroxyebastine, 2H5-carebastine) was added prior to evaporation.  Samples and standards were 
resolubilized in 200 μL of 1 M formic acid in acetonitrile and analyzed by LC-MS-MS.  Cell proteins 
were quantified using the BCA Pierce Kit. 
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7-Ethoxyresorufin Metabolism in Breast Cancer Cell Lines.  Cells were plated in 12 well plates and 
allowed to grow to confluence for 3 days.  Cells were then incubated with 500 μL of various 
concentrations of 7-ethoxyresorufin (0.01 to 1 μM) prepared in DMEM without phenol red or 
serum.  After 5 hour at 37°C, the reaction was stopped by adding 500 μL of internal standard (10 
μg/mL 2H6-hydroxybupropion) prepared in 1 M formic acid in Acetonitrile.  The reaction mixture 
was collected and centrifuged at 13 rpm for 10 minutes.  Samples were analyzed by LC-MS-MS.  
Cell proteins were quantified using the BCA Pierce Kit. 
 
Ebastine and 7-ethoxyresorufin metabolism in recombinant supersomes.  Ebastine was 
incubated in the presence of recombinant CYP2J2 supersomes while 7-ethoxyresorufin was 
incubated in the presence of recombinant CYP1B1 supersomes.  Incubations containing 
supersomes, buffer and an NADPH regenerating system (3.3 mM NADP+, 3.3 mM Glucose-6-
phophate, 5 mM MgCl2 and 0.2 Units of glucose-6-phosphate dehydrogenase) were pre-incubated 
at 37°C for 10 minutes.  To initiate the reaction, various concentrations of ebastine (0.0 to 100 
μM), and 7-ethoxyresorufin (0.01 to 1 μM) were added and incubated at 37°C for 20 and 10 
minutes respectively.  Reactions were terminated by adding two times the volume of internal 
standard prepared in methanol, and placed on ice.  Cells were centrifuged and analyzed by LC-MS-
MS. 
 
LC-MS-MS Analysis:   
Standard solutions Hydroxy ebastine and carebastine stock solutions were prepared in methanol 
at 2.059 mM and 2.001 mM respectively. Resorufin stock solution was prepared in type 1 water at 
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4.69 mM. A series of standard working solutions containing hydroxy ebastine, carebastine and 
resorufin were obtained by diluting the standard stock solutions with methanol. Calibration 
standards were prepared by fortifying incubation media with the standard working solutions at 2% 
(v/v) to enable concentrations spanning the following analytical ranges 4.0 – 2000 nM for hydroxy 
ebastine, 60-30,000 pM for carebastine and 2.0 – 1000 nM for resorufin. The internal standard 
working solution was prepared at 5.0 ng/mL for 2H5-hydroxyebastine, 
2H5-carebastine and 
2H6-
hydroxy bupropion in methanol. 
 
Instrumentation The HPLC system consisted of a Shimadzu Prominence series UFLC pump and 
auto sampler (Kyoto, Japan). The tandem MS system used was a Thermo TSQ Quantum Ultra (San 
Jose, CA, USA). Data were acquired on a Dell Precision desktop computer (Round Rock, TX, USA) 
equipped with operation Windows XP professional. Data acquisition and analysis were performed 
using Xcalibur 2.0.7 (San Jose, CA, USA). Calibration curves were calculated from the equation y = 
ax + b, as determined by weighted (1/x) linear regression of the calibration line constructed from 
the peak-area ratios of the drug to the internal standard. 
 
An isocratic mobile phase was used with a Thermo Scientific Aquasil C18 column (100 x 2.1 mm 
I.D., 5 m) operating at 40°C. The mobile phase conditions consisted of 10 mM ammonium 
formate pH 3.0 and acetonitrile at a ratio of 40:60, respectively. The flow rate was fixed at 0.30 
mL/min and resorufin, carebastine and ebastine eluted at 1.6, 7.3 and 7.4 min, respectively. Five 
microliters of the extracted sample was injected and the total run time was set at 10.0 min. 
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The mass spectrometer was interfaced with the UPLC system using a pneumatic assisted heated 
electrospray ion source. MS detection was performed in positive ion mode, using selected reaction 
monitoring (SRM). The precursor-ion reactions were set at 214.0 → 103.0, 486.1 → 167.0 and 
500.1 → 167.0 for resorufin, hydroxy ebastine and carebastine respectively. The precursor-ion 
reactions for the internal standards were set at 256.0 → 138.9, 491.1 → 171.9 and 505.1 → 172.0 
for the internal standards 2H6-hydroxybupropion, 
2H5-hydroxyebastine and 
2H5-carebastine. In 
order to optimize the MS/MS parameters, a standard solution of each analyte was infused into the 
mass spectrometer.  The following parameters were obtained.  Nitrogen was used for the sheath 
and auxiliary gases and was set at 35 and 20 arbitrary units. The HESI electrode was set to 3000 V. 
The capillary temperature was set at 300°C and its voltage offset was 35 V. Argon was used as 
collision gas at a pressure of 1.5 mTorr.  The collision energy was set at 29 eV for all compounds. 
Scan width for SRM was 0.5 m/z; and scan time 0,1s. Peak width of Q1 and Q3 were both set at 0.7 
FWHM. 
 
Data Analysis The values obtained in the metabolism assays were an average of triplicate 
determination.  The data was fit to the following Michaelis-Menten equation in order to 
determine its kinetic parameters (Vmax and Km) using GraphPad Prism 5 (GraphPad Software, Inc. 
CA, USA); 
  
      
       
 
where x is the substrate concentration, y is the enzyme velocity, Vmax is the maximum 
reaction velocity and Km is the Michaelis-Menten constant. 
 85 
 
      
    
       
 
Where the Vmax is expressed in pmol/mg protein/min and the Km in µM (or pmole/µL), and 
results in a Clint in µL/mg protein/min. 
 
Genomic DNA extraction: Cells were harvested and their genomic DNA was extracted using the kit 
GenElute Blood Genomic DNA kit, Miniprep (Sigma) following manufacturer’s instructions.  
Extracted DNA was then stored at -20°C. 
 
CYP1B1 Sequencing. Using genomic DNA extracted from the breast cancer cell lines, CYP1B1 exons 
2 and 3 were cloned and sequenced.  The CYP1B1 gene is encoded across 3 exons total, however, 
the protein is encoded only on exon 2 and 3.  The primers used for cloning, and sequencing can be 
found in Table 3.  For exon 2 and 3, the following concentrations were used in a total volume of 25 
μL and 50 μL, respectively : 1.25U Taq polymerase, 2 mM MgCl2, 0.2 mM dNTP, 4% DMSO and 0.4 
μM of each primer.   The thermal cycling was as follows: exon 2, an initial denaturation of 95°C for 
4 minutes, following by 35 cycles of 95°C for 1 minutes, 58°C for 45 seconds and 72°C for 4 
minutes, and finished with a final elongation of 10 minutes at 72°C.  For exon 3, an initial 
denaturation of 95°C for 4 minutes, following by 35 cycles of 95°C for 45 seconds, 54°C for 45 
seconds and 72°C for 2 minutes, and finished with a final elongation of 10 minutes at 72°C.  Bands 
were run on a 0.7% agarose gel, and the DNA extracted using the EZ-10 spin column DNA gel 
extraction kit from Bio Basic Inc following manufacturer’s instructions.  Extracted DNA was 
sequenced using the sequencing primers found in Table 3. 
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RESULTS 
Determination of relative expression of CYP450s in breast cancer cell lines.  The relative 
expression of CYP450 mRNAs was evaluated in seven breast cancer, and one benign breast cell 
line.  Table 1 lists the relative expression of each CYP450 enzyme mRNAs by calculating the ∆Ct of 
the isoenzyme to NUP-214, followed by the ∆∆Ct to the Ct value of the median cell line.  For each 
isoenzyme, the cell line which expresses the mRNA the most is highlighted, where the greater the 
value, the greater the expression level.  This data can also be visualized in Figure 1, 2 and 3.  It can 
be seen that certain mRNAs are expressed mainly in one cell line, while others are more evenly 
expressed.  The data shows that CYP450s mRNAs of family 3 (Figure 3) are more strongly 
expressed in MCF-10A cells than in the cancer cell lines.  When comparing the expression of the 
CYP450 family 3 mRNAs in MCF-10A cells to the cell line with the next greatest expression, the 
following is observed.  For CYP3A4, this expression proves to be 4.1 fold higher in MCF-10A 
compared to MDA-MB-231 (p=0.085).  For CYP3A5, the expression is 4.8 fold higher in MCF-10A 
compared to SKBR3 cells (p=0.0184), and finally for CYP3A7, a 26 fold increase is observed 
compared to SKBR3 cells (p=0.041).  CYP1A2 mRNA is another interesting observation where T47D 
cells greatly express this mRNA, while the other cell lines show minimal expression (p=0.0003).  
The selective expression of the CYP3A subfamily in the benign cell line, MCF-10A is of great 
interest.  Since CYP3A4 is the most important enzyme involved in the metabolism of drugs, the 
overexpression of this subfamily in MCF-10A cells would signify a greater clearance capacity of 
many medications from cancer free cells. [20] 
 
Figure 4 graphically represents the expression levels of the various CYP450 mRNAs in each cell line.  
The difference in the Ct values between the values obtained in Table 1 and Figure 4 is in the 
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threshold used to extract the Ct values.  In Table 1, the values were obtained by using the 
individual standard curves for each CYP450 mRNAs.  However, in order to properly compare the 
expression levels for each cell line, the analyses were redone using the standard curve generated 
for the housekeeping gene NUP-214.  Therefore, Figure 4 truly indicates the relative amount of 
each CYP450 mRNAs in each cell line.  Overall, CYP1B1 and 2J2 mRNAs appear to be the most 
important in these cancer cell lines, while CYP1A1 and 1B1 mRNAs are the most important in the 
malignant cell line (MCF-10A), as well as in the cancer cell line Hs578T.   
 
Figure 5 was generated to demonstrate the total CYP450 mRNA expression in each cell line.  
Values were calculated by adding the total relative expressions each cell line and calculating them 
as a percentage.  This data shows that not only does the overall make-up of CYP450 mRNA 
expression change from each cell line, but so does the total CYP450 mRNA expression.  For 
example, MDA-MB-231 and MCF-7 have a much higher total expression of CYP450 mRNAs than 
the other cell lines, whereas Hs578T has very little CYP450 mRNA expression. 
 
Determination CYP450 metabolic potential in breast cancer cell lines.  The metabolic activity of 
the breast cancer cell lines were determined using ebastine as a specific susbtrate of CYP2J2, and 
7-ethoxyresorufin as a substrate of CYP1A1 and 1B1.  The metabolism of these two substrates 
were also evaluated using recombinant supersomes (BD-Canada), where ebastine was incubated 
in the presence of rCYP2J2 and 7-ethoxyresorufin in the presence of rCYP1A1 and 1B1.  The results 
were fit using the Michaelis-Menten equation, and the kinetic parameters were extracted.  Table 2 
lists the kinetic data for both whole cell metabolism and recombinant microsome metabolism 
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whereas the Michaelis-Menten curves and be visualized in Figures 6 and 7 for whole cells only.  
Overall, ebastine metabolism was measurable in all 7 cell lines, where ZR-75-1 showed the 
greatest metabolism and little metabolism was observed in Hs578T, MDA-MB-231 and MCF-10A 
cells.  There Km of ebastine in whole cells has been determined to be around 0.5-1 µM, a value 
that is slightly lower than what is observed in recombinant supersomes (~5 µM).  While these 
values are slightly different, they are within the same low range suggesting that CYP2J2 has a great 
affinity towards ebastine.  The small differences obtained may simply be due to the difference in 
assay conditions, meaning, whole cell incubations compared to supersomes incubations. 
 
When evaluating the metabolism of 7-ethoxyresorufin, measurable activity was only observed in 4 
cell lines.  The Kms obtained were between 0.05 and 0.1 µM in whole cells compared to a Km of 
0.16 µM observed in rCYP1B1 supersomes.  This shows that the affinity obtained in whole cell 
incubations is within the same range as what is observed using CYP1B1 supersomes.  Surprisingly, 
ZR-75-1 and MDA-MB-231 cell lines which express CYP1B1 at a very high level, showed no 
metabolism for this CYP1B1 substrate.  Not even the sequencing data of CYP1B1 for these two cell 
lines could explain the lack of functional activity.   
 
Correlation between mRNA expression and metabolic activity. The correlation between mRNA 
expression and metabolic activity was examined (see Figure 8).  An excellent correlation of 0.9909 
was obtained between the mRNA expression of CYP2J2 and the metabolism potential of ebastine.  
Therefore, this indicates that the large majority of ebastine metabolism is produced by CYP2J2.  
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The correlation of mRNA expression and 7-ethoxyresorfin metabolism was also examined.  Since 
7-ethoxyresorufin is a substrate of CYP1A1, 1A2 and 1B1, all three isoforms were considered.  
However, since CYP1A2 is barely expressed compared to CYP1A1 and 1B1 in these cell lines, the 
metabolism of 7-ethoxyresorufin observed would not be due to CYP1A2.  While both CYP1A1 and 
1B1 are present, the cell lines analysed preferentially express CYP1B1 compared to 1A1 (See Figure 
4).  However, a lack correlation was observed for CYP1A1 and 7-ethoxyresorufin (data not shown, 
with and without MDA-MB-231 and ZR-75-1).  When using the mRNA expression of CYP1B1 and 
7-ethoxyresorufin metabolism, an excellent correlation of 0.9832 was obtained which excluding 
the cell lines MDA-MB-231 and ZR-75-1.  Therefore, this shows that the impact of CYP1A1 in these 
cell lines on the metabolism of 7-ethoxyresorufin is negligible and that the metabolism observed 
in these breast cancer cell lines is due to the presence of CYP1B1. 
 
Determination of CYP1B1 mutations The genotyping of CYP1B1 was then evaluated to determine 
if the lack of 7-ethoxyresorufin metabolism in MDA-MB-231 and ZR-75-1 cell lines was due to 
polymorphisms.  Many mutations of CYPB1 have been documented, both in the intro and exon.  
Genotyping studies were focussed on mutations in the exons since mutations in this region can 
result in amino acid sequence.  Therefore, the portions of the exons encoding for the protein were 
cloned, sequenced and compared to wild type DNA.  Table 4 lists the mutations observed for 
CYP1B1 for all cell lines.   As can be seen, the majority of the cell lines have mutations present 
which include the genotype known as *2 (Arg48Gly, Ala119Ser), *3 (Leu432Val) and *4 
(Asn453Ser).[21]  According to the literature, these three genotypes have been associated with no 
loss in function compared to the wild type protein, and therefore should have no effect on the 
metabolism potential of CYP1B1. 
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DISCUSSION 
Results obtained in this study demonstrate that each cell line has a unique make-up of CYP450 
mRNA expression, which could explain the differential survival of one cell line to another in the 
presence of anti-cancer agents.  We found that the expression of CYP3A4/5/7 mRNAs are greatly 
reduced in the cancer cell lines compared to the benign control, MCF-10A cells.  Therefore new 
active anti-cancer agents that could be metabolised by CYP3 family would be locally detoxified in 
cancer free cells, and remain active longer in breast cancer cells.  We have also shown that mRNA 
expression correlates well to the metabolic activity using two drug probes.  Therefore mRNA 
determination allows for an excellent prediction of enzyme presence. 
 
This study was the first to evaluate the local expression of several CYP450 mRNAs in breast cancer 
cell lines.  The results of this study demonstrate that a large inter-cell line variability was present, 
and that the isoforms abundantly found in breast cancer cell lines were different from the 
isoforms abundantly found in the liver.  These results suggest that the same may be true in 
patients and  that local metabolism may be implicated in the inter-subject variability observed in 
chemotherapy response.   
 
The CYP3A subfamily is of particular interest because of its selective expression, and its large 
involvement in drug metabolism.[20]  In MCF-10A cells, the expression of CYP3A4, 3A5 and 3A7 
mRNAs are greater than in any of the breast cancer cell lines evaluated (41.5, 13.9 and 43.4 times 
more expressed than the median cell line, respectively).  This result shows that the CYP3A 
subfamily is downregulated in breast cancer cell lines, and could be a potential target for new 
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chemotherapy agents.  By synthesizing a chemotherapy agent that is metabolized by CYP3As, the 
administered dose would be cleared from healthy cells faster than from cancerous cells.   CYP19A1 
is another isoform which appears to have preferential expression in the non-malignant cell line.  
CYP19A1 is 13.8 fold more expressed in MCF-10A cells compared to the median cell line (MCF-7) 
and is 7.2 fold more expressed than in MDA-MB-468 cells, the cell line which has the second 
largest expression of this isoform (p<0.0001). 
 
As for the other CYP450 isoenzyme mRNAs, there is no clear difference between the cancer cell 
line and the control, meaning that there is no over- or under-expression in the cancer cell lines 
compared to the control.  However, in some cases, we observed a very large variability in mRNA 
expression levels of enzymes between cell lines.  For example, CYP1A2 mRNA is 46.9 times more 
expressed in T47D cells compared to the median cell line, whereas CYP2J2 mRNA is 14.3 fold more 
expressed in ZR-75-1 compared to the median.  This data therefore shows that there is variability 
in expression from one cell line to the next, and would suggest that this same variability may exist 
between individuals.  Gene variability or inter-individual variability is a phenomenon that is 
commonly observed and can be due to many factors including genetic and environmental. [22]  
Environmental factors are of particular importance in cancer patients because they are often 
exposed to various anti-cancer agents, and potentially to natural products, which are known to 
affect RNA levels through induction and inhibition.  Genetics affect RNA levels in the sense that 
some patients may naturally produce an enzyme more than another (including CYP450s).  This 
could cause toxicity or loss of efficacy of an anticancer agent, through slower or faster metabolic 
rates, respectively.  Overall, there are many sources that can contribute to inter-individual 
variability, which can also be seen in the results obtained in the cell lines.   
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Metabolic studies using ebastine and 7-ethoxyresorufin also displayed an inter-subject variability 
in terms of maximum activity as well as the enzymes affinity to the substrate.  This same variability 
has been observed in human liver microsomes from individual donors for a variety of 
substrates,[23,24]  Therefore, the inter-cell line variability observed is a common phenomenon.  
Overall, the variability in metabolism follows the same variability observed in mRNA expression 
(see Figure 8) and therefore suggests that mRNA expression is an excellent method for predicting 
inter-subject variability.  However, a lack of metabolism of 7-ethoxyresorufin was observed in 
MDA-MB-231 and ZR-75-1 despite the very high level of CYP1B1 mRNA present, compared to the 
other cell lines analyzed.  We attempted to explain this finding by sequencing the exons of CYP1B1 
for all cell lines.  Sequencing data revealed that these two cell lines contain known mutations, 
MDA-MB-231 being genotyped as *2/*2, while ZR-75-1 was genotyped as *1/*4.  Unfortunately, 
previous reports have shown that these genotypes are not expected to lead to a decrease in 
CYP1B1 metabolic activities.[20]  Therefore, the CYP1B1 genotype does not seem to explain the 
lack of activities observed in these two cell lines. The reason for this discrepancy remains unknown 
at this time. 
 
Cytochrome P450 activity is of great importance in chemotherapy treatment because many agents 
are substrates of at least one of the isoenzymes.[25-28]  Since the expression of CYP450 mRNAs, 
and metabolic activities have been displayed in this study for CYP1B1 and 2J2, the local 
metabolism of anti-cancer agents is possible.  Consequently the inter-subject variability in the local 
expression of these isoforms may further contribute to the inter-subject variability observed in 
drug response, particularly of anti-cancer agents.  This suggests that the local metabolism must be 
taken into account. 
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In summary, future anti-cancer agent studies using breast cancer cell lines need to consider these 
results before choosing a cell line for metabolic purposes.  Choosing several cell lines with 
different CYP450 profiles will help determine the efficacy and/or toxicity of new chemotherapy 
agents.  Not only does the overall profile of CYP450 expression vary from one cell line to the next, 
but so does the total metabolism potential of each cell line (Figure 6).  It is important to evaluate 
the total CYP450 mRNA expression because many compounds or medications can be metabolised 
by several CYP450 isoenzymes.  Therefore, a cell line such as ZR-75-1 which expresses a lot of 
CYP450s might metabolise a medication more efficiently than the cell line Hs578T which has very 
little CYP450 expression.  Therefore, several cell lines with different characteristics should be 
evaluated during chemotherapy agent studies. 
 
Overall, this study demonstrates that an important inter-cell line variability in CYP450 mRNAs is 
present in breast cancer cell lines and suggests that this same inter-subject variability may be 
present in breast cancer patients.  The inter-subject differences observed could cause major 
variability in local drug metabolism in breast cancer tumours and therefore explain the large 
variability in drug toxicity and efficacy that is observed.  This study also shows the importance of 
testing potential chemotherapy agents in several breast cancer cell lines in order to determine 
drug efficacy and toxicity. We propose that soectific CYP450s may serve as a new target for future 
anti-cancer agents, since the mRNA expression was downregulated in breast cancer cell lines.  
These new active chemotherapy agents would be locally metabolised and cleared more slowly 
from breast cancer cells and prove to be more efficacious. 
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CONCLUSION 
In conclusion, we performed a thorough determination of the expression level of 19 CYP450 
isoforms in 8 breast cell lines.  This study serves to evaluate the role of CYP450s in the local 
metabolism of medications in breast cancer.  Overall, the results demonstrate that a large inter-
cell line variability is present, both in mRNA expression, and metabolic activities, which would 
suggest that an inter-subject variability may also be present.   
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Table 1: Relative expression of CYP450 mRNAs.   
Table showing the relative expression of each CYP450 mRNA compared to the various cell lines 
using the Standard Curves for each individual enzyme. The cell line which expresses the most 
mRNA of each isoenzyme is highlighted.  Values represent the relative mRNAs expression of each 
isoform, compared to the median expressed cell line. ND: Not detected in cell line. 
CYP450 MCF-10A MCF-7 MDA-MB-468 Hs578T SKBR3 MDA-MB-231 T47D ZR-75-1 
1A1 0.20 0.14 1.00 1.33 0.19 1.75 1.35 0.23 
1A2 0.35 1.00 1.64 0.34 0.17 0.00 46.85 1.48 
1B1 0.20 0.95 2.82 0.03 0.03 4.13 1.00 9.04 
2A6 10.13 1.76 0.57 0.19 0.50 7.94 1.00 0.00 
2B6 0.00 27.35 1.00 0.00 2.02 0.00 89.68 0.38 
2C19 1.93 0.41 0.82 4.97 21.21 0.67 0.06 1.00 
2C8 0.66 76.11 1.27 0.00 0.92 1.00 0.06 2.35 
2C9 ND ND ND ND ND ND ND ND 
2D6 1.00 0.00 0.78 1.01 1.84 0.04 0.04 2.87 
2E1 0.16 1.00 0.03 0.27 5.38 8.13 0.29 12.30 
2J2 0.05 0.57 1.86 0.01 1.84 0.04 1.00 14.29 
2W1 0.00 1.00 2.61 0.00 0.00 5.23 0.71 3.00 
3A4 41.45 0.00 1.00 0.00 0.23 10.06 0.00 7.40 
3A5 13.86 1.00 2.53 0.95 2.87 0.00 0.23 0.00 
3A7 43.26 0.00 1.00 1.06 1.64 0.36 0.00 0.00 
4A11 0.87 1.38 16.04 0.46 1.00 0.00 1.90 0.62 
4Z1 0.73 1.00 176.48 0.08 0.04 0.01 33.44 55.72 
17A1 1.00 0.59 0.49 0.00 2.49 0.42 1.00 3.44 
19A1 13.83 1.00 1.91 1.32 0.00 0.09 0.13 0.04 
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Table 2: Kinetic data for ebastine and 7-ethoxresorufin metabolism in breast cancer cell lines.   
In order to compare whole cell kinetic data, ebastine was incubated with CYP2J2 supersomes, while 7-ethoxyresorufin was incubated in the 
presence of CYP 1B1 supersomes.  BLQ: below level of quantitation. 
Cell Line 
Ebastine Metabolism 7-Ethoxyresorufin Metabolism 
Km  
(µM) 
Vmax 
 (pmol/mg protein/min) 
Cl int 
 (μL/mg protein/min) 
Km  
(µM) 
Vmax  
(pmol/mg protein/min) 
Cl int  
(μL/mg protein/min) 
Hs578T 3.1 ± 0.6 0.13 ± 0.64 0.041 BLQ BLQ BLQ 
MCF-7 1.4 ± 0.2 0.92 ± 0.05 0.642 0.049 ± 0.016 1.456 ± 0.128 29.714 
MCF-10A 0.7 ± 0.2 0.25 ± 0.02 0.339 BLQ BLQ BLQ 
MDA-MB-231 BLQ BLQ BLQ BLQ BLQ BLQ 
MDA-MB-468 0.7 ± 0.1 1.50 ± 0.06 2.286 0.097 ± 0.008 3.709 ± 0.075 38.237 
SKBR3 0.5 ± 0.0 2.45 ± 0.07 4.571 0.055 ± 0.028 0.041 ± 0.006 0.745 
T47D 0.2 ± 0.0 0.58 + 0.015 2.391 0.061 ± 0.027 1.609 ± 0.208 26.377 
ZR-75-1 0.4 ± 0.0 11.49 ± 0.33 30.397 BLQ BLQ BLQ 
rCYP2J2 4.9  ± 0.8 5435 ± 229.6  1100       
rCYP1A1       0.321 ± 0.044 18.120 ± 0.947 56.449 
rCYP1B1       0.157 ± 0.025 4.596 ± 0.217 29.274 
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Table 3: CYP1B1 primers.   
Table lists the primers used for the cloning of exon 2 and 3, as well as the primers used to sequence the complete coding regions of these exons.  
Also listed are the expected band sizes. 
Exon Cloning Primers Sequencing Primers Band Size 
2 
F- 5’ TCT TCG GCC ATT TCT CCA GAG AGT CAG CT 3’ 
R- 5’ACC CCA AAC CCG GGG CCC TGC  TT 3’ 
5’ GCG TGG GGC GCC CGC TCC TG 3’ 
5’ CCC GGT GCG CAC CGT TTT CC 3’ 
1287 bp 
3 
F 5’ CAG GTA TCC TGA TGT GCA GAC T 3’ 
R- 5’ GAG AAG CAG CAC AAA AGA GGA A 3’ 
5’ GAT CAG GTC GTG GGG AGG G 3’ 
5’ TGG TCT AAC CAT TAA ACC CA 3’ 
690 bp 
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Table 4: CYP1B1 observed mutations 
Cell Line Mutations 
Base Pairs 
Mutations 
Amino Acids 
Variant Name 
Hs578T T 1347 C  Heterozogeous Silent Mutation Heterozogeous *1/*1 
MCF-7 T 1347 C  Homozygeous 
A 1358 G Homozygeous 
Silent Mutation 
Asn 453 Ser  Homozygeous 
*4/*4 
MCF-10A C 142 G Heterozygeous 
G 355 T Heterozygeous 
T 1347 C Heterozygeous 
A 1358 G Heterozygeous 
Arg 48 Gly Heterozygeous 
Ala 119 Ser Heterozygeous 
Silent Mutation 
Asn 453 Ser  Heterozygeous 
*2/*4 
MDA-MB-231 C 142 G Homozygeous 
G 355 T Homozygeous 
T 1347 C Homozygeous 
Arg 48 Gly Homozygeous 
Ala 119 Ser Homozygeous 
Silent Mutation 
*2/*2 
MDA-MB-468 C 1294 G Homozygeous Leu 432 Val Homozygeous *3/*3 
SKBR3 C 1294 G Homozygeous Leu 432 Val Homozygeous *3/*3 
T47D C 142 G Homozygeous 
G 355 T Homozygeous 
T 1347 C Homozygeous 
Arg 48 Gly Homozygeous 
Ala 119 Ser Homozygeous 
Silent Mutation 
*2/*2 
ZR-75-1 T 1347 C  Heterozygeous 
A 1358 G Heterozygeous 
Silent Mutation 
Asn 453 Ser  Heterozygeous 
*1/*4 
 
 
99 
 
Figure 1. Relative expression of various CYP450 Families 1, 17 and 19 mRNAs in various breast cancer 
cell lines.   
The cell line with the median ∆Ct was set at a relative expression of 1, and used to compare the 
expression levels of all other cell lines.   
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Figure 2. Relative expression of various CYP450 Family 2 mRNAs in various breast cancer cell lines.   
The cell line with the median ∆Ct was set at a relative expression of 1, and used to compare the 
expression levels of all other cell lines.  CYP2C9 mRNAs is not shown here because only MDA-MB-231 
cells express this enzyme. 
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Figure 3. Relative expression of various CYP450 Family 3 and 4 mRNAs in various breast cancer cell 
lines.   
The cell line with the median ∆Ct was set at a relative expression of 1, and used to compare the 
expression levels of all other cell lines. 
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Figure 4. CYP450 profile of each cell line.  
Indicates the relative expression of CYP450 mRNAs in each cell line, where the Ct values were 
determined for each enzyme using the Standard Curve of NUP-214.  The use of one threshold cut-off 
(one standard curve) permits a comparison of the different isoenzymes in each cell line. 
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Figure 5. Expression of total CYP450 mRNA in each cell line.   
This indicates which cell like has the most CYP450 total mRNA expression.  ZR-75-1 proves to be the cell 
line with the greatest expression of CYP450 mRNAs, while Hs578T has very little CYP450 mRNA 
expression.  Values were calculated by adding the total relative expressions each cell line and calculating 
them as a percentage. 
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Figure 6. Ebastine metabolism in breast cancer cell lines.   
Metabolism rates were corrected for protein concentration and time (1 hour incubations).  The 
metabolism of Ebastine is a measure of CYP2J2 activity.  SKBR3 shows the greatest metabolism of 
Ebastine of the cell lines analyzed. 
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Figure 7. 7-Ethoxyresorufin metabolism in breast cancer cell lines.   
Metabolism rates were corrected for protein concentration and time (5 hour incubations).  
MDA-MB-468 demonstrates the greatest 7-ethoxyresorufin metabolism with no auto-inhibition from 
0-1 µM.  Measurable activity was observed for T47D and MCF-7 cells, however, above 0.5 µM, an 
auto-inhibition is observed, and therefore concentrations above this concentration were removed prior 
to kinetic calculations. 
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Figure 8. Correlation studies of mRNA expression and metabolic activity.   
The correlation between CYP2J2 mRNA expression and metabolism of ebastine is displayed in red, and 
shows an excellent correlation of 0.9909.  In blue is the correlation between CYP1B1 mRNA expression 
and the metabolism of 7-ethoxyresorufin.  This correlation of 0.9832 was calculated excluding ZR-75-1 
and MDA-MB-231 because they were outliers. 
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GENERAL DISCUSSION AND PERSPECTIVES 
The response and efficacy of anti-cancer agents in breast cancer have been known to vary 
greatly from individual to individual.  Since many of the anti-cancer agents used to treat breast cancer 
are substrates of various Cytochrome P450s (CYP450), the variability in expression of these enzymes 
could greatly impact the plasmatic concentrations of the anti-cancer agents.  Consequently, the 
response and efficacy of these medications could be affected.  Therefore, the main objective of these 
studies was to evaluate the expression of nineteen CYP450 mRNAs, in order to determine which 
isoforms are greatly expressed, and if the expression between different cell lines shows a large inter-
subject variability. 
 
In order to evaluate the expression of CYP450 mRNAs, RT-PCR studies were completed using the 
delta-delta Ct method.  In order to correct for RNA integrity and cDNA concentration differences 
between samples, a housekeeping gene (HKG) is used as a calibrator.  Consequently, the key to good 
quality RT-PCR data is choosing a HKG that is ubiquitously expressed despite tissue source, pathology or 
inter-subject variability.  Traditionally, GAPDH and β-actin have served as, and continue to serve as 
HKGs.  However, preliminary studies completed in our laboratory showed that the expression of these 
two commonly used HKGs were highly variable within the breast cancer cell lines of interest.  These 
results lead to the screening of six different genes, GAPDH, β-Actin, RPLPO, TBP, NUP-214 and PPIG 
across the breast cancer cell lines of interest as well as in 15 other cell lines, which were isolated from a 
variety of tissue sources.   
 
After analyzing the expression level, the stability of the six HKGs was determined by calculating 
the standard deviation and the deviation from average for each gene.  In order to confirm our results, an 
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online database specific for HKG analyses was also used.  The database permitted our results to be 
imputed and analyzed by a variety of techniques.[1]  Each analysis method lead to the same conclusion: 
NUP-214 was the most stable HKG analyzed.   
 
These results were the first study to demonstrate that one gene, namely NUP-214, was not only 
the most stable within the same tissue source, but also across various tissue sources.  Analyses using 
NUP-214 as the HKG will lead to more reliable and convincing results, and will permit cross-organ 
studies.  Therefore, these results should have a significant impact in RT-PCR studies, where future 
analyses using this technique should greatly consider switching from the traditional HKGs, GAPDH and 
β-actin to NUP-214.   
 
 Our next goal was to evaluate the mRNA expression level of 19 CYP450 isoforms in 7 breast 
cancer cell lines and 1 benign breast cell line.  By evaluating which isoforms are highly expressed in the 
breast cancer cell lines, we could better understand if these enzymes may play a key role in the 
clearance of anti-cancer agents, and therefore be causing inter-subject variability.  By comparing the 
expression level of CYP450 isoforms in the benign cell line compared to the breast cancer cell lines, we 
were able to evaluate if any isoforms are up- or down-regulated in breast cancer.   
 
 The results obtained in this study demonstrate that the CYP450 mRNA make-up is unique to 
each cell line, and that the overall expression of total CYP450s varied greatly between cell lines.  
Therefore each cell line would interact with xenobiotics in very a different way, where certain cell lines 
may be more or less sensitive to CYP450 metabolized xenobiotics.  This would therefore explain the 
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differential survival of cell lines when in the presence of anti-cancer agents.  These results would suggest 
that new anti-cancer agents need to be tested on several breast cancer cell lines in order to determine if 
a medication is efficacious or not.  Currently several cell lines may be evaluated during this process.  
However, their selection may be chosen based on cell receptor presence (ER, PR and HER2) as opposed 
to the CYP450 make-up.  A more concrete cell line selection should take into account all of these factors. 
 
 When evaluating the expression of CYP450 isoforms between the benign cell line, MCF-10A and 
the breast cancer cell lines, one subfamily, the CYP3A, showed a significantly lower expression in the 
breast cancer cell lines compared to the benign cell line.  This selective expression is of great interest 
because the CYP3A family, specifically the CYP3A4 isoform, is largely involved in the metabolism of many 
different medications.[2]  With this differential metabolism in mind, the development of new anti-
cancer agents that are primarily metabolized by CYP3A4/5/7 would be ideal because a high clearance in 
normal breast cells would be present, and therefore would lead to the targeting of breast cancer cells. 
  
Another isoform that shows differential expression between malignant and cancer cell lines is 
CYP19A1.  This isoform was significantly more expressed in the control cell line, MCF-10A, then in the 
breast cancer cell lines.  This result is quite interesting because CYP19A1, otherwise known for its 
aromatase activity, has been a target of interest for breast cancer treatment.  Aromatase is one of the 
key enzymes involved in the biosynthesis of estrogen, and has been shown to be greatly expressed in 
breast cells. [3-4]  Since previous reports have shown an elevated expression of CYP19A1 in breast cells, 
aromatase inhibitors (Anastrozole, Exemestane and Letrozole) are used to treat breast tumors in post-
menopausal, ER+ tumors. [5-6]  If the same expression pattern of CYP19A1 is also observed in breast 
cancer patients, it would mean that the aromatase inhibitors would be more significantly decreasing the 
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production of estrogen in the normal breast cells than in the cancer cells.  If the cancer cells are ER+, 
they would require estrogen to stimulate their growth, and therefore by decreasing the surrounding 
concentration of estrogen would inhibit the growth of the cancer cells.  These results would suggest that 
the targeted cells of these inhibitors would not directly be the cancer cells, but the normal breast cells. 
 
This study also revealed that the two most abundant isoforms present in the breast cancer cell 
lines are CYP1B1 and CYP2J2.  These two isoforms are important to evaluate because of their different 
roles.  The high expression of CYP1B1 is not too surprising because of its involvement in the metabolisms 
of hormone, specifically the hydroxylation of 17β-estradiol and testosterone.[7]  Furthermore, CYP1B1 
expression has been linked to the production of pre-carcinogenic molecules (benzanthracene, 
benzo(a)pyrine, DMBA, 1-ethynyl-pyrene, 3-methyl-cholantrene and oestradiol), and is believed to be a 
source of steroid hormone-mediated cancers. [7-9]  Therefore, a significant expression of CYP1B1 is to 
be expected in breast cancer cells.  Since CYP1B1 is capable of metabolizing hormones, anti-cancer 
agents that resemble hormones, such as SERMs, could be locally metabolized by this isoform.  Future 
metabolic studies of this class of anti-cancer agents using CYP1B1 supersomes would be very interesting. 
 
The role of CYP2J2 is substantially different from that of CYP1B1.  Its role is quite diverse, 
because not only is this enzyme involved in the metabolism of endogenous molecules, such as fatty 
acids, arachidonic and linoleic acid, but is also involved in the metabolism of a great number of 
xenobiotics.[2, 10-13]  Since the active site of CYP2J2 is so similar to that of CYP3A4 (just slightly 
narrower), many of the xenobiotics metabolized by CYP3A4 are also substrates of CYP2J2. [10, 14]  Since 
there is such a lack of CYP3A4 in the breast cancer cell lines analyzed, CYP2J2 may be a replacement for 
the isoform, and therefore the role of CYP2J2 in the local metabolism of xenobiotics needs to be 
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evaluated.  Since CYP3A4 is involved in the metabolism of many anti-cancer agents, such as 
cyclophosphamide, paclitaxel, docetaxel, tamoxifen and exemestane, metabolism studies of these 
medications using recombinant CYP2J2 supersomes would be extremely interesting. [10, 15-31]  
Understanding if these treatments can be locally metabolized by CYP450s will allow for better adjusted 
dosing for breast cancer patients and should ultimately lead to better patient treatment and survival. 
  
Finally, metabolism studies to demonstrate the activity of CYP2J2 and CYP1B1 were completed 
using two probe drugs, ebastine and 7-ethoxyresorufin, respectively.  While a lack of metabolism of 
7-ethoxyresorufin was observed in two cell lines (MDA-MD-231 and ZR-75-1) despite an elevated 
expression of CYP1B1, a strong correlation remains present between this isoform and its substrate.  The 
lack of metabolism for these two cell lines could not be explained through the genotyping of the coding 
region, and therefore the reason is unknown at this time.  The mRNA expression of CYP2J2 and ebastine 
metabolism showed an excellent correlation where a substantial amount of metabolism was observed 
after only a one hour incubation.  These metabolic studies revealed that an inter-subject variability is 
present for the cell lines, when evaluating their maximum activity, as well as their substrate affinities.  
Therefore, this study not only insinuates that substantial local metabolism is possible, but also that local 
metabolism may impact the inter-subject response to medications.   
  
Overall, this project was comprised of several interesting and important results.  The first 
analysis revealed a new and more stably expressed HKG for RT-PCR analyses, NUP-214.  This HKG is 
more ubiquitously expressed than other genes, such as GAPDH, despite tissue source or pathology.  
Therefore this study demonstrates the need to change from traditional HKGs to NUP-214.  The second 
study demonstrated that an important inter-cell line variability in CYP450 mRNAs is present in breast 
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cancer cell lines.  This study suggests that inter-subject variability may also be present in breast cancer 
patients and that the local metabolism could therefore be an additional cause to the toxicity and 
response differences currently observed in patients.  This research suggests that CYP1B1 and CYP2J2 
may be significantly impacting the local concentration of anti-cancer agents in breast cancer cells, and 
therefore decreasing the efficacy of certain medications, specifically in patients with a high expression of 
CYP1B or 2J2.  Therefore, future metabolism studies of these isoforms with various chemotherapy 
agents could be extremely interesting and lead to important results.  This study also suggests that during 
the development of future chemotherapy agents, several breast cancer lines should be screened to 
determine drug efficacy and toxicity since inter-cell line variability was so high.  We propose that 
CYP450s that are downregulated in breast cancer cell lines, could serve as new targets for anti-cancer 
agents.  This would lead to anti-cancer agents that are cleared more slowly from breast cancer cell lines, 
leading to higher intracellular concentrations and therefore more efficacious medications. 
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GENERAL CONCLUSIONS 
Breast cancer is a disease which affects thousands of women and men in Canada yearly.  Some 
breast cancer patients have shown a de novo and acquired resistance to anti-cancer agents, resulting in 
a treatment failure.  Identifying potential causes for this resistance is required in order to develop better 
treatment options which could avoid these causes.  Some studies have shown that factors affecting drug 
disposition, such as membrane transporters could affect the local concentrations of anti-cancer agents 
in the targeted cells.  Other enzymes which could influence the cellular concentrations of these agents 
are the metabolizing enzymes, Cytochrome P450s.  Many chemotherapy agents are known substrates of 
one or many CYP450 isoforms, and therefore CYP450s locally expressed in breast cancer cells could 
greatly decrease the cellular concentration of these treatments.  Therefore, the objective of this work 
was to evaluate the expression of CYP450 mRNAs locally expressed in breast cancer cell lines and to 
determine if their expressions could be significant enough to affect the intracellular drug 
concentrations. 
Prior to determining CYP450 mRNA expression by RT-PCR, a screening of potential housekeeping 
genes was completed in order to determine which gene was the most stably expressed.  In order to 
complete this study, the stability of six candidate HKGs (β-Actin, GAPDH, NUP-214, PPIG, RPLPO, TBP) 
was determined in twenty-three different cell lines (coming from different pathologies and isolated from 
different tissues).  Overall, the results demonstrate that NUP-214 is the most stable HKG candidate, and 
was expressed in all cell lines tested at a very similar level.  Therefore NUP-214 can be considered a 
universal HKG. 
Using NUP-214 as the HKG, the expression level of 19 CYP450 isoforms in 8 breast cancer cell 
lines (1 of which is a benign breast cell line) was determined.  The results showed that many CYP450s 
are expressed locally in these cell lines, and that the isoforms found in these cells are not the same 
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isoforms expressed hepatically.  Specifically, CYP1B1 and 2J2, two isoforms which are considered extra-
hepatic isoforms are very strongly expressed in these cell lines.   Furthermore, a large inter-cell line 
variability in CYP450 expression was observed in these cell lines.  Using specific metabolic substrates of 
CYP1B1 and 2J2, namely, 7-ethoxyresorufin and ebastine, respectively, metabolism studies were 
completed.  These studies demonstrated that not only are these cell lines capable of locally metabolizing 
substrates, but also that the metabolism of these two substrates correlates very well with mRNA 
expression.   
This is the first time that whole cell metabolism studies were completed using breast cancer cell 
lines.  This study was therefore the first to demonstrate the potential that local metabolism may play in 
the chemoresistance in breast cancer cells.  In specific, CYP1B1 and 2J2 may play a significant role in the 
metabolism of chemotherapy agents.  Since these two isoforms are not highly expressed in the liver, 
they are not evaluated during the in vitro drug metabolism process.  Future studies need to be 
completed in order to evaluate the potential metabolism of various anti-cancer agents by these two 
isoforms.   
Overall, these results would suggest that an inter-subject variability in CYP450 mRNA expression 
may be present in breast cancer patients, and that their local expression could be significant enough to 
modulate the local cellular concentrations of anti-cancer agents.  In conclusion, this study demonstrates, 
for the first time, that CYP450s are significantly present in breast cancer cells, and that their local 
expressions need to be considered during anti-cancer drug development. 
 
 
 
 
 
125 
 
 
 
 
 
 
 
 
                                                       ANNEX 1      
             
          
 DECLARATION OF CO-AUTHORS 
 
 
